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ABSTRACT 
 
          Radiation therapy (RT) plays currently significant role in curative treatments of several 
cancers. External beam RT is carried out mostly by using megavoltage beams of linear 
accelerators. Tumor eradication and normal tissue complications correlate to dose absorbed in 
tissues. Normally this dependence is steep and it is crucial that actual dose within patient 
accurately correspond to the planned dose. All factors in a RT procedure contain uncertainties 
requiring strict quality assurance.  
          From hospital physicist´s point of a view, technical quality control (QC), dose 
calculations and methods for verification of correct treatment location are the most important 
subjects. Most important factor in technical QC is the verification that radiation production of 
an accelerator, called output, is within narrow acceptable limits. The output measurements are 
carried out according to a locally chosen dosimetric QC program defining measurement time 
interval and action levels. Dose calculation algorithms need to be configured for the 
accelerators by using measured beam data. The uncertainty of such data sets limits for best 
achievable calculation accuracy. All these dosimetric measurements require good experience, 
are workful, take up resources needed for treatments and are prone to several random and 
systematic sources of errors. Appropriate verification of treatment location is more important 
in intensity modulated radiation therapy (IMRT) than in conventional RT. This is due to steep 
dose gradients produced within or close to healthy tissues locating only a few millimetres 
from the targeted volume. 
          The thesis was concentrated in investigation of the quality of dosimetric measurements, 
the efficacy of dosimetric QC programs, the verification of measured beam data and the effect 
of positional errors on the dose received by the major salivary glands in head and neck IMRT. 
A method was developed for the estimation of the effect of the use of different dosimetric QC 
programs on the overall uncertainty of dose. Data were provided to facilitate the choice of a 
sufficient QC program. The method takes into account local output stability and 
reproducibility of the dosimetric QC measurements. A method based on the model fitting of 
the results of the QC measurements was proposed for the estimation of both of these factors. 
The reduction of random measurement errors and optimization of QC procedure were also 
investigated. A method and suggestions were presented for these purposes. The accuracy of 
beam data was evaluated in Finnish RT centres. Sufficient accuracy level was estimated for 
the beam data. A method based on the use of reference beam data was developed for the QC 
of beam data. Dosimetric and geometric accuracy requirements were evaluated for head and 
neck IMRT when function of the major salivary glands is intended to be spared. These criteria 
are based on the dose response obtained for the glands. 
          Random measurement errors could be reduced enabling lowering of action levels and 
prolongation of measurement time interval from 1 month to even 6 months simultaneously 
maintaining dose accuracy. The combined effect of the proposed methods, suggestions and 
criteria was found to facilitate the avoidance of maximal dose errors of up to even about 8 %. 
In addition, their use may make the strictest recommended overall dose accuracy level of 3 % 
(1SD) achievable. 
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1. INTRODUCTION 
 
 
The purpose of radiation therapy (RT) is to maximize killing of cancer cells in a tissue by 
using ionizing radiation while maximizing or keeping the sparing of healhy cells at acceptable 
level. Currently, external RT is most usually carried out by using linear accelerators proving 
high energy x-rays. This so called “megavoltage (MV)” radiation penetrates deeply into 
tissues enabling treatment of central parts of body with reasonable amount of dose delivered 
to superficial structures near the skin. RT is applied for several types of cancer but as well for 
some benign diseases. RT can be given as an exclusive treatment technique or combined with 
surgery and/or chemotherapy. RT is currently well available treatment technique in western 
world. 
 
The role of RT as a curative or palliative treatment technique is significant and is currently 
increasing (Delaney et al. 2005, Elshaikh et al. 2006). Considering Finland alone, the number 
of RT centres was 9 at the time of data collection for this thesis (years 2003-2005) and has 
increased to 12 until time of the writing of this thesis (the beginning of year 2009), and, 
moreover, one private RT centre is starting treatment activity during a few months. One of the 
main reasons for the increase of the use of RT has been the development of technology of 
linear accelerators providing faster, more accurate and more reproducible treatment delivery 
in the sense of both dose and geometry. As a consequence, irradiation of normal tissues near a 
targeted volume has been reduced since smaller marginals are needed around the target. On 
the other hand, knowledge of radiation response of tissues has increased. 
 
Considering the physical radiation quantities, biological effects correlate to absorbed dose 
received by a tissue. In some cases, the dependence is observed to be steep suggesting strict 
accuracy requirements for both absolute value of dose and the location where it is delived. 
Considering huge amount of patients treated annually by RT, it is expected that increased 
accuracy for both of the former factors has significant effect. Several international and 
national recommendations have been made for procedures to reach and to maintain a 
sufficient accuracy level. Most of the recommendations give accuracy limits for physical 
parameters based on practically achievable limits. Since the success of tumor destruction and 
avoidance of adverse biological effects are the only clinical measures for the success of the 
curative RT, estimation of accuracy requirements and benefits of improvements on biological 
basis is desirable. Unfortunately, the estimation of biological effects is difficult due to their 
complex nature including many sources of uncertainty and factors specific for a certain cancer 
and a treatment technique. Therefore, estimations based on biological effects are at their best 
only for special cases. General situation can be approached by doing estimations for ‘average’ 
dose response characteristics but application of such estimations may be limited. 
 
The accuracy of absorbed dose delivered to a patient depends on several factors. These 
include quality of dosimetry, dosimetric and geometric accuracy of dose delivery, accuracy of 
dose calculation within a patient, quality of radiological images, treatment planning process, 
reproducibility of patient set-up during a treatment and correction strategy of patient 
positional errors during a treatment. From hospital physicist’s point of view, quality control 
(QC) procedures concentrate on all these factors from the choice of good quality equipments 
and softwares to appropriate measurement procedures. Also development of methods for 
image quidance and patient set-up verification and immobilization is essential. 
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The most important aim for good dose accuracy is the maintenance of a narrow deviation in 
the radiation production of an accelerator. The radiation production is called ‘output’ and it is 
defined as the dose absorbed at a reference point in a beam per a monitor unit (MU) measured 
by accelerator monitoring chamber (Gy/MU). Shift of the output level results in changes of 
the doses received by all patients. The maintenance of good dosimetric accuracy in treatments 
depends on the stability of an accelerator, reproducibility of QC measurements and the ability 
of the used QC procedure in the detection of true drifts in the beam parameters. The output is 
measured at regular time intervals accurately in a water tank by using a very stabile reference 
instrument. The measurements are carried out with relatively long time intervals since they 
are workful and time consuming. Approximative constancy checks (CC) of output are carried 
out more often by using by fast and easily movable equipment. A CC device may not be very 
stabile requiring regular calibrations against the local reference instrument. 
 
The use of an appropriate QC procedure for output should maximize the detection of both 
‘normal’ and unexpected changes in output levels. QC programs given by different 
international or national authorities have recommended considerable variable time intervals 
for the output measurements ranging from one week to even one year. Intuitively it is safer to 
have short output measurement intervals but too redundant measurements waste resources and 
time that could be used for treatments. The RT centres have to choose their QC program 
intuitively without quantitative data of the efficacy of the use of the chosen program on the 
overall accuracy of dose. The elaboration and optimization of a local QC program would 
require the knowledge of normal time pattern in output level to estimate output stability and 
suitable time intervals for the measurements. Such knowledge might also facilitate the 
detection of potential malfunctions and measurement errors. The knowledge of measurement 
reproducibility is crucial in the choice of appropriate action levels for the measurements and 
in the evaluation of appropriate remedying actions for measured output changes. Due to 
relatively long output measurement time intervals, the reproducibility of the approximate CCs 
should be sufficient in the detection of output changes of only a few per cent with very few 
check repetitions. Moreover, long-term stability of a CC device should be sufficient (or 
known) with respect to the chosen output measurement time interval. All the factors 
mentioned above may depend on accelerator and dosimetric equipment types. 
 
In addition to output, accuracy of dose calculations is one of the most crucial factors in the 
achievement of good overall dosimetric accuracy. A hospital physicist should choose 
appropriate calculation algorithm and verify that the measured basic beam data used to 
configure the calculation algorithm are accurate. The quality of measured beam data sets 
baseline for the accuracy level achievable for all dose calculations. The recognition of 
systematic measurement errors is difficult and methods are desired to identify such errors 
preferably already during a measurement session. The identification of sources for potentially 
poor calculation accuracy is desirable to avoid unnecessary and workful remeasurements of 
correct beam data sets. There is no consencus between the centres what accuracy level should 
be considered sufficient for the basic beam data. 
 
Patient set-up errors have an important effect on the dose received by the target and normal 
tissues. Their magnitude, effect on the dose and related biological effects can be accurately 
estimated only in special cases. In intensity modulated radiation therapy (IMRT), the role of 
patient set-up errors is more prominent than in conventional RT due to steep dose gradients 
within or close to normal tissues located near the target produced by moving leafs of multileaf 
collimator during a treatment. An interesting special case of IMRT is head and neck IMRT, 
where substantial part of function of one or more of the major salivary glands is intended to 
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be spared. Salivary glands are quite radiation sensitive, they might locate at a distance of only 
few millimetres from the target and they are relatively small when compared to the target. The 
knowledge of geometric accuracy required for the treatments would be of a great clinical 
value. Evaluations of such requirement based on the dose response characteristics of the 
glands have not been published. 
 
This thesis was concentrated in the investigation of the quality of dosimetric QC 
measurements, the efficacy and optimization of QC programs for the dosimetric 
measurements, and the quality of basic beam data used to configure dose calculation 
algorithm. The uncertainty related to these factors has a direct effect on the accuracy of dose 
received by all patients. Methods, suggestions and criteria were proposed to improve dose 
accuracy and to verify that the uncertainty related to the investigated factors is not too high 
when compared with the uncertainty of other factors currently achievable. Overall uncertainty 
of dose and the combined effect of the proposed factors to improve it were estimated. 
Biological effects related to the improvements were estimated for the general situation by 
using literature data. In addition to these factors, patient set-up accuracy and the effect of 
positional errors on the dose received by the major salivary glands were investigated in head 
and neck IMRT. Both dosimetric and geometric accuracy requirements were estimated for the 
case when substantial part of salivary gland function is intended to be spared. The 
requirements were based on the dose response characteristics obtained for the major salivary 
glands and dose gradients within the glands. 
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2. THEORETICAL BACKGROUND 
 
 
This section contains a literature review and is aimed to give an overall impression of RT 
describing the basic concepts, therapy procedures and quality assurance. It clarifies the 
importance and central role of the investigated topics for the quality of treatments. On the 
other hand, the theory and international recommendations related to the investigated topics are 
presented in this section. 
 
 
2.1. DOSE RESPONSE IN RADIOTHERAPY 
 
Absorbed dose D is defined as the mean energy E imparted by ionizing radiation to matter of 
mass m:  
 
 
  
dm
dED =                                    (1) 
 
 
The unit of D is Gray (Gy) [J/kg]. This physical quantity of radiation is found to correlate 
with biological effects releated to RT and the word “dose” means absorbed dose in this thesis. 
 
Biological effects such as normal tissue complications and tumor eradication depend on the 
dose distributions within these tissues. Dose volume dependence has been parametrized by 
proposing several mathematical models (Schultheiss et al. 1983, Lyman 1985, Kutcher et al. 
1991, Källman et al. 1992, Niemierko 1997, 1999). Two extreme types observed for dose 
volume relationship suggest that tissue inner structure can be modelled by either a serial or 
parallel architecture of functional units (Burman et al. 1991). Destruction of one functional 
unit may lead to a complication in a serially structured tissue rendering the NTCP dependent 
on maximum dose within the tissue. In a parallelly structured tissue, e.g. kidney, lung and 
salivary gland, the NTCP correlates best with mean dose within the tissue. TCP correlates 
usually best to minimum dose or minimum dose delivered to 95 % volume of a tumor 
(Withers 2000). 
 
The general relationship between the dose and the probability of a biological effect has been 
observed to be sigmoidal for over 70 years ago (Holthusen 1936). This relationship, called 
dose response, is commonly parametrized by fitting a logistic model function of form 
 
 
Γ
D
D ⎟⎠
⎞⎜⎝
⎛+
=
501
1NTCP                                                                                       (2) 
 
 
to clinical data, where NTCP is the probability of a complication, and D50 and Γ are fitting 
parameters specific for the tissue and the complication. The parameter D50 gives the dose 
resulting in 50% probability of complication. Also the probability of eradication of a tumor, 
known as tumor control probability (TCP), can be parametrized by using the sigmoidal model. 
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The sigmoidal dose response can be approximated by a linear model within a narrow range of 
dose values. 
 
The most important feature of the sigmoidal dose response is weak dependence of biological 
effects on dose with low (D << D50) and high (D >> D50) dose values. On the contrary, with 
intermediate dose values (D ≈ D50) a small change of dose results in significant change of 
NTCP or TCP (Figure 2-1). The steepness of the dose response is usually expressed by 
normalizing the derivative of NTCP as (Brahme 1984)  
 
 
(%)
NTCP(%)NTCP
D
D
dD
d
∆
∆≈=γ     (3) 
 
 
giving a dimensionless quantity for the steepness. The reported values of γ  have varied 
typically from about 1 (Cheung et al. 2005a) to about 6 (Levegrün et al. 2001) depending on 
selected biological endpoint, cancer type and subgroup of patients. The value of about 3 has 
been considered as a general mean (Okunieff et al. 1995). 
 
Irradiated volume in a patient contains both targeted and normal tissues. An overall risk 
related to a treatment can be estimated by combining the parametrized models of NTCP and 
TCP resulting in an estimate for the probability of uncomplicated cure PUC = TCP(1-NTCP) 
(Figure 2-1). The NTCP and TCP curves are usually steep and close to each other in the dose 
axis resulting in a narrow PUC curve. This sets biological basis for strict dose accuracy 
requirements in RT. Besides the biological aspects, high dose accuracy is essential for 
comparisons of treatment techniques and results between centres. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1. The sigmoidal dose response models for tumor control probability (TCP, solid 
line) and normal tissue complication probability (NTCP, dashed line). The probability of 
uncomplicated cure (PUC, dotted line) is close to its maximal value within a relatively 
narrow range of dose values. 
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The current dose response models are not capable for describing individual variations in 
radiation sensitivity. The models provide only percentages of complications and tumor control 
for a group of patients receiving equal and uniform dose. Combined effect of individual 
radiation sensitivity and uncertainty in quantification of biological effects is remarkable 
resulting in large scatter of data points and relatively large confidence limits for the values of 
the fitting parameters. 
 
 
2.2. DETERMINATION OF DOSE WITHIN A PATIENT IN EXTERNAL PHOTON  
       BEAM RADIOTHERAPY 
 
2.2.1. Dose measurements 
 
The determination of absorbed dose within a patient is based on the measurement of absorbed 
dose in water, since mean electron density of soft tissues is close to that of water. The 
measurements are based on Bragg-Gray cavity theory (Bragg 1912, Gray 1936) and its further 
improvements (Burlin 1966) assuming that i) the air cavity of a measuring instrument does 
not change the energy spectrum of secondary electrons, ii) photons produce only negligible 
amount of secondary electrons in the air cavity and iii) the flux of photons is constant in the 
air cavity and in its surroundings. A small (< 1 cm3) air filled thimble type ionization chamber 
with thin walls fullfills best these assumptions and is recommended for the reference tool of 
clinical dosimetry. Chambers with graphite walls have been found to have better long-term 
stability and more constant response for different x-ray beam energies than chambers with 
plastic walls. A commonly used ionization chamber for photon beam dosimetry is open 0.6 cc 
Farmer-type NE 2571 (NE Technology Ltd, Reading, UK). 
 
The dosimetry of the RT equipment is carried out by following of one of the internationally 
recommended dosimetric code of practice. At the moment, the TRS-398 given by the 
International Atomic Energy Agency (IAEA 2000) is used in Finland. Electric charge 
(ionization) formed in a chamber is collected by high voltage and measured by an 
electrometer and needs to be calibrated to absorbed dose value. The radiotherapy centres 
calibrate their ionization chamber in a secondary standard dosimetry laboratory (SSDL) where 
the calibration is carried out in the 60Co beam against a secondary standard of absorbed dose. 
The calibration is valid in reference conditions with temperature 20 oC and athmospheric 
pressure 101.3 kPa, and correction is required for actual measurement conditions. The 
calibration is traceable to a primary standard. According to IAEA, the accuracy of the 
calibration of a clinical dosimetry instrument is 0.6 % (1SD) when calibrated in a SSDL. 
 
The calibration coefficient of a chamber should be corrected for the nominal energy of user’s 
x-ray beam. The correction factor is given in the dosimetric code of practice and is based on 
the value of a beam quality index (QI). Finally, the dose absorbed in water for radiation of 
quality Q is given as 
 
 
QQ NkkkkMD w,elecpolsTpw, ⋅⋅⋅⋅⋅=     (4) 
 
 
where M is reading of an electrometer and correction factors kTp, ks, kpol and kelec are for 
conversion of actual measurement conditions to reference conditions, for recombination of 
ion pairs before they are collected, for polarity of collecting voltage and for sensitity of 
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electrometer, respectively. Nw,Q is the calibration coefficient of the chamber for dose absorbed 
in water for radiation of quality Q.  
 
For the QI, the TRS-398 recommends measurement of tissue phantom ratio ( 2010TPR , ratio of 
doses at depths of 20 and 10 cm) or ratio of depth ionizations at depths 10 and 20 cm ( 1020J ≡ 
J10/J20) for a field size of 10x10 cm2. According to the TRS-398 these quantities are 
empirically related as 
 
 
0595.01.2661TPR 10
20
20
10 −= J      (5) 
 
 
According to IAEA (2000), overall uncertainty of clinical absorbed dose measurements is 1.5 
% (1SD) and a measurement procedure carried out in user’s beam gives the most significant 
contribution to this being even 1.4 % (1SD). The latter is devided into 5 factors: 1) long-term 
stability of user dosimeter 0.3 %, 2) establishment of reference conditions 0.4 %, 3) dosimeter 
reading relative to beam monitor 0.6 %, 4) correction for influence quantities (ki) 0.4 % and 5) 
beam quality correction 1.0 %. The accuracy of absorbed dose measurements could be 
significantly improved if the uncertainty of the measurements carried out in the user’s beam 
could be reduced. 
 
2.2.2. Dose calculation 
 
A treatment is administered in monitor units (MUs) measured by two independent monitoring 
chambers within an accelerator’s head. The purpose of dose calculation is to estimate dose 
within a patient and to calculate the number of MUs needed for planned dose delivery for 
each field. Reference methods for dose calculation are based on Monte Carlo (MC) (Demarco 
et al. 1998). For clinical purposes, however, dose calculation should be done in times of few 
minutes and approximative analytical calculation models are used instead of the more 
physical MC models. In the Nordic countries, the most commonly used calculation methods 
for photon beams are the pencil beam convolution (PBC) (Storchi et al. 1999) and the 
collapsed cone convolution (CCC) (Ahnesjö 1989). In this thesis, the dose calculations are 
carried out by using the PBC and quality of beam data used to configure this model are 
evaluated. The principles of the PBC model and the equations relating the configuration beam 
data to measured dose values are presented. 
 
The PBC method 
 
The PBC method devides therapy beam into small cylindrical beams of radius 0.5 cm. 
Absorbed dose is calculated in a water phantom for a field F using the equation (Storchi et al. 
1999) 
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where F(x,y) is field intensity matrix, Pint(x,y,d) intensity profile and K(x,y,d) is pencil beam 
kernel. The F(x,y) include field geometry and its value is 1 in an open part of the field, 0 
outside the field and equal to the fraction of transmission of MLC under the part of the field 
shielded by the MLC. Pint(x,y,d) is normalized fluence of primary photons accounting for the 
non-flatness of the open field beam and variations of photon fluence due to variation of 
energy spectrum as a function of off-axis distance. The x and y are coordinate axis in the 
directions parallel to the width and height of the field, respectively, d is the depth to which 
dose is calculated and dref is the reference depth. SPD is the distance from the x-ray source to 
the surface of the phantom. The convolution is done at 5 standard depths and the dose is 
interpolated along fanlines for other depths. Finally, the dose distribution is corrected to take 
into account correct source to skin distance (SSD), tissue inhomogeneities and oblique 
incidence of the beam to a patient. 
 
Basic beam data and their relation to calculated number of MUs 
 
Three types of basic beam data should be measured to configure the PBC model. The 
Pint(x,y,d) and K(x,y,d) are determined iteratively from the measured data (Storchi et al. 1999). 
The measurements are carried out in a large water phantom with recommended miminum size 
of 30x30x30 cm3 conventionally by using the SPD of 100 cm. The measured data are 
converted into relative form and, therefore, absorbed dose calibration of a beam has to be 
done only at one reference point. The types of the required beam data are: 
 
1) Measurement of depth dose data for square fields XxX is recommeded at least for field side         
X = smallest, 4, 6, 8, 10, 12, 15, 20, 25, 30, 35 and 40 cm. The data is normalized to dose (D) 
at the depth of dose maximum (dmax) giving percentage depth dose data (PDD) defined as 
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PDD data for a rectangular field XxY are taken from the PDD of an equivalent square field 
calculated to give the same dose at 10 cm depth as the field XxY. 
 
2) The number of monitor units (MU) providing a certain dose (e.g. 1 Gy) at dmax should be 
measured for all rectangular field sizes. Field size resolution of 1 cm is recommended. The 
number of MUs obtained for a field size XxY is normalized to the number of MUs obtained 
for a reference field size 10x10 cm2 resulting in an output factor (OF) defined as 
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The OFs of rectangular fields can be used to calculate OFs for asymmetric and dynamic 
wedge fields (Tenhunen 1994). 
 
3) The PBC model requires measurement of beam profiles for the square fields at least at 
three depths, but five measurement depths of dmax, 5, 10, 20 and 30 cm are recommended. 
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Measurements should be done for the same field sizes for which PDDs were measured. Peaks 
caused by noise in the profiles capable of causing error in the normalization of the profile on 
the central axis are handled by curve fitting through the center of the profile. A weighted 
average between the fit and measured curve is used. In addition, the diagonal profile is needed 
for the largest open field size. 
 
At the geometry of beam data measurements, the dose D delivered to a water phantom is 
calculated from a simple equation showing explicit dependence of D on the measured beam 
data. The number of MUs required for a delivery of D to the depth d at the central axis of a 
square non-MLC field XxX is calculated as 
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where MU10x10 is the number of MUs measured to deliver the same dose to the dmax of the 
reference 10x10 cm2 field. The Equation (9) demonstrates the impact of the accuracy of OF 
and PDD data on the accuracy of the dose calculated at the central axis of a field. Dose 
calculated at an off-axis point is normalized to the dose at the central axis and, therefore, the 
accuracy of the central axis dose forms a baseline for the accuracy of dose calculation at the 
other points in a field. For a rectangular field XxY, the Equation (9) becomes 
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where PSF is the phantom scatter factor and c is the side of an equivalent square field 
resulting in the same central axis D at a depth of 10 cm as the field XxY (calculated according 
to the Eq. 6). The PSF values are taken from a table obtained by the NCS (Van Gasteren et al. 
1991) by taking into account the QI of the beam (Storchi and Van Gasteren 1996). If SSD is 
different from that used in the beam data measurements (SPD), the PDD data are corrected by 
using the formula (Khan 2003, p. 172)  
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being based on the Mayneord F factor (Mayneord and Lamerton 1944) corrected by T(d,c) 
ratio, where T(d,c) is tissue maximum ratio (TMR) or tissue air ratio (TAR) value at depth d 
for a field having an equivalent field size c at the field entry level. The TMR is determined 
from the measured beam data as (Khan 2003, p. 196) 
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where FSd is field size at depth d and refFSd is field size at depth dref. 
 
2.2.3. Radiation therapy procedures 
 
First phase of the RT procedures is aquisition of adequate anatomical and functional 
information for the planning of a target volume in a patient. Geometric reference of patient 
anatomy is a 3D tomography image (CT) series or sometimes a magnetic resonance image 
(MRI) series, in which the target is drawn by a radiation oncologist. The planning of the target 
may require registration of images from different imaging modalities. Patient position in the 
reference image series should be accurately reproduced in each treatment fraction requiring 
sufficient patient immobilization technique and patient set-up verification during the 
treatment. Isocenter of therapy beams is currently chosen when the reference image series is 
acquired. When necessary, the position of the isocenter can be verified by simulating the 
patient set-up in a treatment simulator where x-ray images can be aquired from the directions 
of the therapy beams. For the set-up verification, at least two orthogonal reference images 
containing suitable land marks (usually bones and/or air cavities) are acquired or 
reconstructed from the reference series by using a treatment planning system (TPS).  
 
Treatment planning is carried out by choosing the number, orientation, shape, radiation type 
and energy of the therapy beams and also dose fractionation scheme. The location of the 
target and critical organs is accurately visualized by the TPS and the dose distribution within a 
patient can be calculated to the reference anatomical image series. Uniform dose distribution 
of prescribed dose is aimed for the target while irradiation of normal tissues is minimized by 
proper choice of field orientations and shapes. Treatments are often delivered by using static 
fields shaped conformal to target by using multileaf collimator (MLC). MLC consists usually 
from 80 to 120 leafs of a width 0.5-1.0 cm independently adjustable to bound the target while 
blocking normal tissues. 
 
Image guidance is used in RT meaning that anatomic images are acquired during the 
treatment. The locations of the land marks between those images and the reference image are 
determined by on-line image registration and observed differences are corrected before 
treatment delivery. The use of cone beam CT acquistions (CBCT) during the treatment has 
currently increased providing information of the deformation of tissue structures. The quality 
of CBCT images sometimes makes it possible to replan a treatment to correspond potentially 
changed patient anatomy. 
 
With recent years, the use of intensity modulated treatment technique (IMRT) (Brahme et al. 
1982, AAPM 2003, Bortfeld et al. 2006, Meyer 2007) has increased significantly. In that 
technique, highly conformal dose distribution is achieved usually by moving the leafs of the 
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MLC during the irradiation. In IMRT, flatness of dose distribution within the target is 
compromised to enhanced normal tissue sparing near the target. Inverse treatment planning 
method is utilized by setting constraints for dose and volume of the target and critical normal 
tissues (Brahme 1988, Brahme 1995, Webb 1997). A function containing suitable penalties 
for unfulfilled constraints is minimized resulting in an optimized photon fluence matrix for 
each treatment field providing optimal dose distribution within a patient. The optimal fluence 
is converted into actual fluence by calculating tables for MLC movement and by taking tissue 
inhomogeneities within a patient into account (Svensson et al. 1994, Webb 1997). An 
alternative approach to inverse IMRT treatment planning is forward planning (fIMRT) 
achieved recently increasing interest (Kestin et al. 2000, Xiao et al. 2000, Chen et al. 2001, 
Lee et al. 2004). In that technique, basic field set-up is planned first and dose distribution 
within patient calculated. After this, low dose regions within the target and hot spots within 
normal tissues are corrected by adding constraints or fields targeted to the low dose areas 
while shielding the areas of hot spots. 
 
Each RT procedure is prone to several sources of uncertainty requiring appropriate quality 
assurance. With a physical point of view, the important factors are proper contrast and 
geometric scaling of the images used for the treatment planning, accuracy of image 
registration, appropriate patient fixation providing well reproducible positioning, proper 
patient set-up verification, knowledge of the nature and effects of positional errors, and 
correction methods for such errors during the treatment. 
 
 
2.3. CLINICAL QUALITY ASSURANCE 
 
2.3.1. General aspects  
 
International Organization for Standardization (ISO) has defined that the quality is ”the 
totality of features and characteristics of a product or service that bear on its ability to satisfy 
stated or implied needs” (ISO 1994). Practically this means that a patient should have 
relevantly planned and realized therapy. The quality assurance (QA) should comprehend 
whole treatment process from the prescription of the therapy to the follow up of the patient. 
At a clinical level QA should concern quality policy, organization, methods, equipment, and 
education as described in the comprehensive international QA recommendations (Kutcher et 
al. 1994, Thwaites et al. 1995). From a physicist’s point of view, the QA can be captured to 
mean the verification that the planned dose value is delivered to the planned location in a 
patient. Any deviation from the treatment plan may lead to unexpected complications or loss 
of treatment efficacy, and hampers comparison of methods in a centre and between centres. 
Methodological QA is required to ensure the choise of relevant treatment technique and 
planning method, while technical QA is needed for accurate realization of the treatment plan. 
Quality control (QC) describes practical actions related to QA. 
 
The ISO has recommended that estimated accuracy should be expressed in uncertainties (ISO 
1995). Fundamentally, the uncertainties can be classified into type-A which can be estimated 
by statistical means and type-B estimated by other means. Both of these types are expressed 
by standard deviation (SD) and overall uncertainty is the combination of the uncertainties of 
the both types estimated for all factors involved in a process. Gaussian uncertainties of 
independent sources are summed in squares. QA aims to reduce the uncertainty of the both 
type A and B. 
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Several recommendations exist for maximal uncertainty of dose within a RT patient: ± 3 % 
(1SD) given by Brahme et al. (1988), ± 3.5 % (1SD) given by Mijnheer et al. (1987) and ± 5 
% (interpreted as 95% CI) given by ICRU (1976). The estimations made by Brahme et al. and 
ICRU are based on conclusions made for dose response of some types of tumors while 
Mijnheer et al. investigated NTCP. Moreover, IAEA has concluded in the TRS-398 that ± 5 
% (1SD) might be a sufficient accuracy level. The differences in these recommendations can 
be understood by considering the complex nature of biological effects rendering 
recommendations at general level difficult. Since the studies included in this thesis 
concentrate to both dosimetric and geometric QA, these topics and also most important 
recommendations relating to the investigations are introduced. 
 
2.3.2. Dosimetric quality assurance 
 
Dosimetric quality assurance should comprehend all radiation therapy procedures affecting 
the value of the dose absorbed to a patient. From a physical point of view, the main topics of 
dosimetric QA are the accuracy of dosimetric measurements, the maintainance of dose output 
of an accelerator in the predefined tolerance limits and the accuracy of dose calculation. 
 
Dose measurements 
 
QC for a reference ionizing chamber comprehends regular calibrations at a standards 
laboratory and verification for long-term stability of the calibration before each absorbed dose 
measurement by using a radioactive check source. Before an absorbed dose measurement, 
flatness of beam profiles indicating correct beam orientation and depth dose data indicating 
correct beam energy should be measured for reference field size. Absorbed dose 
measurements used for the calibration of a beam are often called ‘output measurements’ since 
they measure dose production (Gy/MU) of a linear accelerator. In this thesis, the dose 
production is called ‘output’ and the absorbed dose measurements are called ‘output 
measurements’. 
 
The output measurements are carried out in a large water phantom (minimum size 30x30x30 
cm3) at reference geometry at a reference point for a reference field size, usually 10x10 cm2. 
The output measurements carried out as described above are workfull and are often called 
“definitive calibrations” and they are performed rarely. “Routine calibrations” are performed 
more often by using the reference ionizing chamber but they can be carried out in a smaller 
water or solid (e.g. PMMA) phantom. These calibrations can be converted into definitive 
calibrations (Seuntjens et al. 2005). Approximative constancy checks (CC) are performed 
frequently, preferably daily. Very commonly used istrument is a sealed plane parallel ionizing 
chamber which is larger and has lower spatial resolution than the reference chamber but is not 
so fragile. Unfortunately, CC devices are usually not stable requiring regular calibrations 
against the reference chamber. 
 
QC programs in RT centres have remarkable differencies. Several international QC programs 
have been published recommending considerable different time intervals for the output 
measurements ranging from one week (IPEM 1999, SSRPM 2003) or two weeks (NCS 1996) 
to even one year (WHO 1988, Dunscombe et al. 2007). Also time intervals laying somewhere 
between these have been proposed being one month (NACP 1980, Kutcher et al. 1994, IPEM 
1999) and 3 months (NACP 1980). The most recommended action levels for the output 
measurements are ± 2 % (NACP 1980, IEC 1989, Kutcher et al. 1994, IPEM 1999, SSRPM 
2003). Also wider action levels being ± 3 % (Aird et al. 2007) have been suggested, while 
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some centres have been reported to use very narrow tolerance levels from ± 0.75 % to ± 1.5 % 
(Meijer et al. 1998, Luketina and Greig 2004). Moreover, an output calibration program 
without tolerances, interpreted as an output calibration exactly to a measured value, has been 
proposed (WHO 1988). Some centres define tolerance as action level while other consider 
excess of tolerance level as an indicator for increased control for the treatment unit 
performance. In unclear situations, the term ‘tolerance’ is used here as it was in the cited 
literature. The centres have to define and document procedures for remedies relating to the 
excess of the predefined action levels. For the daily CCs, action levels of ± 3 % (Kutcher et 
al. 1994, SSRPM 2003) or ± 5 % (IPEM 1999) have been recommended. 
 
Approaches to optimize a local QC program 
 
The investigation of time trends in dosimetric parameters such as output (Watanabe 2000, 
Kristensen et al. 2003, Krutman et al. 2004, Luketina and Greig 2004, Tuncel et al. 2004) or 
beam energy (Biggs 2003) has recently been increasing. The results have been utilized for 
fine tuning a local QC program in the sense of measurement time interval and action levels 
but the latter has received more attention. The action levels are conventionally estimated by 
using the mean and standard deviation of a measured parameter (Cozzi and Fogliata-Cozzi 
1998, Van Esch et al. 2000), but also a more sophisticated method to improve the detection of 
systematic shifts in outputs based on statistical process control has been published (Pawlicki 
et al. 2005). Only a few publications exist on seeking evidence for the effectiveness of a use 
of a certain output measurement time interval and action levels (McKenzie 2003, McKenzie 
et al. 2005, 2006). These studies have attempted to balance the costs of resources spent for the 
QC procedures and the costs related to significant underdosage of patients not detected by the 
QC procedures resulting in tumor recurrence and loss of lives. In these studies, it was clearly 
stated that such cost-benefit analysis includes several sources of uncertainty and they are 
based on theoretic assumptions or worst case scenarios of output changes and their detection 
instead of real observations. Therefore, the benefits and costs related to a QC program remain 
highly uncertain. 
 
Beam data and dose calculation 
 
QC of dose calculation concerns the quality of basic beam data used for the configuration of 
TPS and the accuracy of dose calculations for realistic situations emphasizing uncertainty 
inherent to a calculation algorithm. These categories are usually mixed together mistakenly 
but considerable different accuracy criteria exist for these categories. 
 
Dose calculation accuracy at the central axis of open (non-MLC) rectangular fields is most 
explicitely related to the accuracy of basic beam data used for the TPS configuration (as was 
seen in 2.2.2.) and reflects best accuracy achievable for all dose calculations for that beam. 
Several recommendations exist for accuracy criteria for open square fields ranging from 1 % 
(Fraass et al. 1998, IPEM 1999) to 2 % (Ahnesjö and Aspradakis 1999, Venselaar et al. 
2001). For open rectangular fields the corresponding criteria are from 1.5 % (Fraass et al. 
1998) to 2 % (Ahnesjö and Aspradakis 1999, Venselaar et al. 2001). For a normalization 
point at central axis of a regtangular open field, defined as OF, stricter accuracy criterion of 
0.5 % (Fraass et al. 1998) has been recommended. 
 
For dose calculations in realistic treatment situations, lower accuracy criteria are suggested. 
The most cited ICRU Report 42 (1987) has recommended the tightest accuracy criterion of 
2% for low dose gradient areas or 2 mm for high dose gradient areas. Consistently, by 
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combining uncertainty related to the RT procedures it has been concluded that dose 
calculation does not need to be more accurate than 2-3 % while 1 % is as an ultimate goal 
(Ahnesjö and Aspradakis 1999). On practical basis it has been estimated that accuracy of 3-4 
% or 3-4 mm for high dose gradient regions is achievable (Van Dyk et al. 1993, IPEM 1999, 
Venselaar et al. 2001). In the presence of large 3D inhomogeneities, remarkably lower 
accuracy criteria of 5-7 % or 7 mm in penumbra region have been considered acceptable 
(Fraass et al. 1998). The criteria are interpreted to concern all calculation points or concerned 
as 95 % CI for these points. Several QC programs have been published for the TPS utilizing 
conventional static therapy fields (Fraass et al. 1998, AAPM 2001, Venselaar and Welleweerd 
2001, Venselaar et al. 2001, ESTRO 2004, IAEA 2004) and also for systems utilizing modern 
delivery methods such as IMRT fields (Van Esch et al. 2002, ESTRO 2008, ICRU 2009). 
 
Some elaborate QC methods have been proposed to evaluate the accuracy of central axis 
beam data based on parametric presentation of the TPR (Bjärngard et al. 1997, Xiao et al. 
1998). The implementation of these methods requires measurements of beam attenuation and 
hardening coefficients in a narrow-beam geometry and/or several measurements of the TPRs. 
Due to the generality of these methods, they provide an accuracy level of about 1-2 % for FSs 
larger than 10x10 cm2 and in the region of electron equilibrium. Another approach to QC of 
beam data is the comparison of measured beam data to standardized reference beam data. 
Based on observations of great consistency in beam data measured for the accelerators of the 
same make, model and energy, the Radiological Physics Center (RPC) in the USA has started 
construction of comprehensive reference data sets for several accelerator models of different 
vendors (Followill et al. 2004). The utilization of reference data for QC is much simpler than 
the use of the elaborated methods. It is not clear, however, whether the proposed methods are 
accurate enough in the detection of relatively small errors exceeding the strict accuracy 
criteria of ± 1 % recommended for the basic beam data. 
 
External audits for radiotherapy dosimetry 
 
The purpose of external audits is the review of local RT procedures by an independent 
external body. The dosimetry audits can be carried out by on-site review visits and/or off-site 
reviews by using mailed dosimeters. The on-site audits comprehend checks of local dosimetry 
systems, tests of dosimetry parameters of RT equipment, tests of TPSs, review of QA 
programmes and review of dosimetry records. On on-site audits, the dosimetric checks are 
usually carried out by ionizing chamber measurements in a water phantom while 
thermoluminescence dosimeters (TLDs) are most commonly used for the mailed reviews. 
Most on-site audits are carried out at national level by a national authority such as the 
Radiation and Nuclear Safety Authority (STUK) in Finland (Järvinen et al. 2001). The three 
major TLD networks are the IAEA/WHO (World Health Organization) TLD postal dose audit 
service operating worldwide (Svensson et al. 1990, Izewska and Andreo 2000), the European 
Society for Therapeutic Radiology and Oncology (ESTRO) EQUAL program operating in the 
European Union (Ferreira et al. 2000) and the RPC network operating in North America 
(Hanson et al. 1991, Aguirre et al. 2002). The EQUAL network has been linked to the 
European Commission network (Dutreix et al. 1994). 
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2.3.3. Geometric quality assurance 
 
Geometric QA should comprehend all radiation therapy procedures affecting the location to 
which the dose is delivered in a patient. Geometric accuracy is more crucial in IMRT than in 
conventional RT due to steep dose gradients. 
 
Geometric accuracy requirements for a treatment unit concerns size of radiation field, size of 
light field, position of MLC leafs, position of radiation isocenter, position of geometric 
isocenter, collimator rotation, gantry rotation, position of treatment couch and quality of an 
imaging device. High geometrical accuracy is required also for anatomical data used for the 
treatment planning concerning the phases from the data acquisition and correct data transfer to 
the capability of a TPS to handle the data accurately. Several QC recommendations and 
programs have been published for testing all these technical factors including action levels for 
remedies (Kutcher et al. 1994, IPEM 1999, SSRPM 2003). 
 
Accuracy of patient set-up depends on a treatment location in a patient, patient fixation 
technique, method used for isocenter positioning, image guidance method used for position 
verification and, to some extent, co-operation of the patient. In addition, the target volume 
may move within a patient e.g. due to breathing movement. Uncertainty related to these 
factors is taken into account by planning a treatment to a volume including margins added 
around clinical target volume (CTV), encompassing clinically obvious gross tumor volume 
(GTV) and its potential subclinical spreading, resulting in the use of planning target volume 
(PTV) (ICRU 1993, ICRU 1999). QA is aimed to ensure that acceptable methodology is used 
to confirm sufficient reproducibility for patient set-up and coverage of PTV irradiation while 
minizing margins needed around CTV to minimize irradiation of normal tissues. Sometimes 
margins are added around critical normal tissues in a treatment plan to maximize their sparing 
resulting in the use of planning organ at risk volume (PRV). Comprehensive and detailed 
summary of sources of positional uncertainty and their estimated magnitudes for different 
treatment locations is given by the British Institute of Radiology (BIR 2003). 
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3. AIMS OF THE THESIS 
 
 
The aim of the thesis was to estimate uncertainty of absorbed dose of radiotherapy patients 
related to treatment and dosimetry procedures, such as quality control measurements, 
commissioning of a treatment planning system, and patient set-up. Some practical methods, 
suggestions and criteria were proposed to improve the accuracy of the absorbed dose. The 
specific aims of the study were: 
 
1. to estimate reproducibility of output measurements of linear accelerators, to assess 
reproducibility and long-term stability of constancy checks of output, to investigate typical 
time behaviour of output to elaborate and optimize quality control procedures, to propose 
methods for the estimation of all these subjects. (Study I). 
 
2. to evaluate the effectiveness of different internationally recommended quality control 
programs for output measurements by taking into account reproducibility of output 
measurements and constancy checks of output, and stability of output. (Study II). 
 
3. to evaluate the accuracy of basic beam data used for the configuration of treatment 
planning systems in Finnish radiotherapy centres, to determine dose calculation accuracy at 
reference geometry, to evaluate practically achievable accuracy criterion for central axis dose 
calculations, to find out potential reasons for reduced dose calculation accuracy, to estimate 
consistency of beam data for the most commonly used accelerator models, to develop a 
method for quality control of basic beam data. (Study III). 
 
4. to determine the magnitude of set-up errors in head and neck IMRT, to estimate the effect 
of positional errors on the dose received by the major salivary glands, to determine dose 
response model parameters for planned dose of the salivary glands, to estimate dosimetric and 
geometric accuracy requirements for the head and neck IMRT in the case when substantial 
fraction of salivary gland function is intended to be spared. (Study IV). 
 
5. In the thesis, the effectiveness of the methods, suggestions and criteria proposed in Studies 
I-IV was summed. Combined uncertainty of dose and its improvements were estimated. 
Related biological effects were also assessed. 
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4. MATERIALS AND METHODS 
 
 
4.1. STUDY MATERIAL 
 
4.1.1. Quality control data 
 
The QC data collected by the Department of Oncology, Helsinki University Central Hospital 
(HUCH), between January 2000 and December 2004 were analyzed to determine short- and 
long-term time trends in accelerator outputs and the reproducibility of the output 
measurements and the CCs of outputs. The data had been collected for photon external beams 
of eigth linear accelerators, including one Varian Clinac 600 C (6 MV), two 600 CDs (6 MV), 
one 2100 C (6 and 15 MV), two 2100 CDs (6 and 15 or 18 MV) (Varian Medical Systems, 
Palo Alto, CA), one BrainLab Novalis (6 MV) (BrainLab, Heimstetten, Germany) and one 
Elekta SL18 (6 and 15 MV, Elekta Oncology Systems, Crawley, UK). The output 
measurements had been carried out by experienced hospital physicists at the depth of 10 cm in 
a 10×10 cm2 beam at maximal time intervals of 6 months by using a 0.6 cc open ionization 
chamber type NE 2571 and NE Farmer 2570 electrometer (NE Technology Ltd, Reading, 
UK). The equipment had been calibrated at years 2000 and 2003 in the national secondary 
standard laboratory (STUK) and the constancy of the calibration had been checked before 
each measurement by using a check source and also by comparative measurements in 
connection with on-site visits by the STUK several times a year. The CCs of the outputs had 
been carried out two or three times a week by the RT technologists by using four sealed plane 
parallel ionization chambers of type PTW-Linacheck T42010 (PTW, Freiburg, Germany). 
One device was used per two accelerators. The CC devices had been calibrated in connection 
with the output measurements. Relative dosimetry comprehending the checks of beam 
profiles and depth dose (QI) was carried out before each output measurement by using a 0.13 
cc open ionization chamber (Wellhöfer IC15, Scanditronix-Wellhöfer, Uppsala, Sweden) and 
a Wellhöfer WP700 scanning water tank with Dosimetrie WP700 software (Wellhöfer 
Dosimetrie, Schwarzenbruck, Germany). 
 
4.1.2. Measurements for dose calculation accuracy and beam data 
 
Dose measurements 
 
Measurements used for the evaluation of dose calculation accuracy were carried out by the 
STUK during site visits in the Finnish RT centres between the years 2003 and 2005. The 
measurements were performed for 48 photon beams from 28 accelerators including all 9 RT 
centres in Finland. The absolute dosimetry was carried out by using a 0.6 cc Farmer type 
ionization chamber (NE 2571) and an electrometer (NE Farmer 2570). The chamber and 
electrometer calibrations came from the Finnish SSDL in STUK and were traceable to the 
primary normal of the International Bureau of Weights and Measures (BIPM). On the site 
visits, parameters related to beam profiles (symmetry, flatness and penumbra) and energy 
( 1020J  and/or 
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10TPR ) were verified to be consistent with the values measured in connection 
with institution’s beam data measurements. 
 
The accelerators included in the analysis were 7 Varian Clinac 600 Cs or CDs (4-6 MV), 18 
Varian Clinac 2100 Cs or CDs (6, 15 or 18 MV), 1 Varian Clinac 2100 SC (6, 10 MV), 1 
Elekta SL 75-5 (6 MV) and 1 Elekta SL 18 (6, 15 MV). One out of 29 accelerators in Finland 
was excluded because it was a stereotactic machine with limited field sizes. 
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Dose calculations 
 
Dose calculations for the dose delivery measured by the STUK were carried out by a hospital 
physicist. The number of monitor units (MUs) for an isocentric central axis dose delivery of 2 
Gy at the depth of 10 cm in water (SAD=100 cm, SSD=90 cm) were calculated for the 
following FSs (XxY): 5x5, 7x7, 10x10, 15x15, 20x20, 30x30, 40x40, 5x30 and 30x5 cm2. 
Calculations were performed by using the single PBC algorithm implemented in CadPlan® 
(Varian Medical Systems, Helsinki, Finland) or Eclipse® (Varian Medical Systems, Palo 
Alto, CA) TPS software.  
 
Basic beam data 
 
OF and PDD data used for the configuration of TPS were collected from all 9 Finnish RT 
centres for the analysis. The geometry set-ups used for the basic beam data and the absorbed 
dose measurements are shown in Figure 4-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1. a) The geometry set-up used for basic beam data measurements in connection 
with local TPS configuration and for local beam calibrations. b) The geometry set-up used for 
the dose measurements to determine calculation accuracy. The depth of field size definition is 
indicated as FS.  
 
 
4.1.3. Patient material 
 
Patient and tumor characteristics 
 
Data of 25 patients scheduled to be treated by bilateral radiation therapy for head and neck 
squamous cell cancer between the years 2005-2007 were analyzed to estimate patient set-up 
errors, the effect of set-up errors on the dose received by the major salivary glands and dose 
response characteristics of the major salivary glands. Pretreatment staging of the tumors had 
been done by clinical examination, MRI and endoscopy, and biopsies had been taken from the 
primary tumor and, when necessary, from clinically suspicious lymph nodes. The tumors had 
been staged according to the International Union Against Cancer (UICC) Tumor-Node-
Metastasis (TNM) classification version 2002. More detailed main characteristics of the 
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patients and tumors are presented in Study IV (Table 1). Thirteen patients received definitive 
radiotherapy with curative intent and 12 patients received postoperative radiotherapy. Total 
doses varied from 50 to 70 Gy received at 2 Gy fractions. Concurrent weekly cisplatin 
40mg/m2 was given to all 13 patients treated by definitive radiotherapy and to 6 of the 12 
patients treated by postoperative radiotherapy. The patients belong to a group participating in 
a prospective study of head and neck radiotherapy approved by an Ethics Committee of the 
Helsinki University Central Hospital. The current investigations did not change the treatment 
practice of these patients. 
 
Measurement of salivary gland function 
 
Individual salivary gland function had been carried out by scintigraphy. The method has been 
described earlier in detail by Tenhunen et al. (2008). In brief, the scintigraphy had been 
performed by using an intravenous injection of Tc-99m-pertechnetate (185 MBq) and a 
dynamic series of anterior images had been collected with Toshiba GCA-7200A/UI gamma 
camera (Toshiba Corporation, Tokyo, Japan) equipped with a low-energy high-resolution 
collimator. Regions of interest (ROI) had been placed on each major salivary gland and on the 
background. The individual salivary gland ejection fraction (EF) describing the magnitude of 
salivary secretion due to stimulus was calculated from the ROIs. Stimulated saliva production 
had been achieved by using 20-40 ml of 25 % lemon juice administered 15 min after the 
tracer injection. The assessment of the EFs had been performed before radiotherapy and 6 
months after the therapy for each patient. 
 
Major salivary glands without observable pretreatment function were excluded from the 
analysis. The volumes (mean ± SD) of the included parotids were 17.0 ± 7.3 cm3 (range: 7.1-
32.4 cm3, N=41) and those of the submandibular glands were 4.9 ± 1.9 cm3 (range: 2.8-9.1 
cm3, N=17). 
 
4.1.4. Determination of patient set-up errors and their effect on major salivary gland     
          mean dose 
 
Determination of set-up errors and their effect on dose 
 
A stereotactic head and neck immobilization device was used (BrainLab, Heimstetten, 
Germany). The isocenter localization was based on stereotactic coordinates computed by 
using BrainLab stereotactic TPS. Positional shift of a salivary gland with respect to the 
therapy beams was approximated from the positional shift of the bony structures near the 
gland. The shift was defined as the difference between their locations in two orthogonal portal 
images and two reference X-ray images taken in connection with the treatment simulation. 
The shifts were obtained in three orthogonal dimensions (1D) and they were combined to 
obtain also a three dimensional shift (3D). Portal imaging was carried out in two first 
treatment fractions and, thereafter, at least weekly for each patient. Mean of set-up variations 
during treatment indicating systematic set-up error that would have occurred without 
correction of patient positioning and standard deviation (SD) of the set-up variations 
indicating random set-up error were calculated for each patient. Rotational shifts were 
converted into translational shifts and were not explicitly presented. At the time of the 
collection of the patient data, a systematic positional shift in one of the three orthogonal 
directions (1D) ≥ 3 mm detected by the portal images was verified by resimulating the patient 
positioning and when necessary by correcting the positioning with respect to the stereotactic 
coordinates. 
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The effect of patient set-up errors on the mean doses of the major salivary glands that would 
have occurred without corrections of patient positioning was estimated by using the TPS. The 
planned isocenter was moved according to the obtained systematic shift and the dose 
distributions within the glands were recalculated without changing the field fluence 
distributions and the number of monitor units. 
 
Treatment planning 
 
The IMRT technique has been previously described in detail (Saarilahti et al. 2005, 2006). 
Dose distributions were calculated by using the single PBC algorithm implemented in 
Eclipse® TPS software (Varian Medical Systems, Palo Alto, CA). Tissue inhomogeneity 
correction was carried out by using the modified Batho method (Batho 1964, Young and 
Gaylord 1970). After conventional TPS configuration, a proper width of the PBC kernel, 
crucial for accurate dose calculations in IMRT, was readjusted and confirmed through film 
measurements of treatment fields to produce acceptable dose calculation accuracy for IMRT 
test fields (Van Esch et al. 2002). All 25 patients were treated with the same Varian Clinac 
600 CD (6 MV) linear accelerator (Varian Medical Systems, Palo Alto, CA) equipped with 
Millenium 120 MLC (leaf width 0.5 cm). 
 
 
4.2 ANALYZING METHODOLOGY 
 
4.2.1. Analysis of quality control measurements 
  
Short-term behaviour of an output level 
 
A systematic short-term (time period between two successive output measurements) drift in 
an output level of a linear accelerator was determined by fitting a linear model 
 
  
tbatg ′+′=)(      (13) 
 
 
to the results of the CCs (Figure 4-2), where a´ and b´ are the fitting parameters and t is the 
time. The results of the CCs were corrected for a systematic drift in the calibration of the CC 
device. Each obtained linear trend was compared to a trend formed by the successive output 
measurements. 
 
For statistical analysis of output behaviour, empirical probability distributions were 
constructed for the obtained linear output trends for both low and high photon energy regions. 
The probability of a trend was determined by dividing its duration by the sum of the durations 
of all trends. Total duration of the trends was about 8400 and 4300 days for 6 and 15-18 MV, 
respectively. 
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Figure 4-2. According to the constancy checks (‘x’s with a solid line), a systematic short-term 
drift in an output level was assumed linear (dashed line) between two successive output 
measurements (squares). 
 
 
Long-term behaviour of an output level 
 
A ‘free’ cumulated systematic long-term (time period of more than two successive output 
measurements) drift in an output level, which most likely would have occurred without any 
dose adjustments, was estimated for each accelerator and photon energy. This was done by 
arranging consecutively the linear short-term trends formed by two successive output 
measurements. The linear model (Eq. (13)) or a non-linear model with an empirically 
determined form was fitted to each constructed data set. 
 
Since the model with most fitting parameters is not necessarily the best one due to random 
errors in the data, the model chosen for a data set gave minimal value for the Akaike 
information criterion AIC (Akaike 1974) defined as 
 
 
β2])(ln[AIC 2 +∆= ∑ errN     (14) 
       
 
where β  is the number of parameters (β  = 2 for g(t)), N is the number of data points and 
Σ(∆err)2 is the sum of the squared fitting errors of a model. 
 
If the monitor chamber of an accelerator was replaced, a construction of new set of data was 
started from that day on. If a dosimetrically significant repair or an adjustment was carried out 
between successive output measurements (such as adjustment of beam profile, energy, dose 
rate, RF-power or RF-frequency), a trend in output for that time interval was determined by 
fitting the linear model to the results of the CCs measured before that repair or adjustment. 
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As complementary results to those presented in the publications, the efficacy of the empirical 
model fitting of the QC measurement results was investigated in the improvement of dose 
accuracy. The reduction of random errors was evaluated when a current measurement result is 
estimated and future value predicted from the fitted model. These were carried out by 
simulating random measurement errors by using two different measurement reproducibility 
levels and by model fitting the simulated data. Linear time trend was assumed in the fitted 
parameter. Finally, the effect of potentially reduced random measurement errors on the 
deviation of output was estimated. 
 
Reproducibility of output measurements 
 
The reproducibility of the output measurements was estimated by using two different 
approaches: i) from the SD of the fitting errors of the long-term models of the output and ii) 
from the SD of differences between comparative measurements of the hospital and the STUK 
carried out on the site visits by using independent measurement devices and measurement set-
ups. The former method i) combines the uncertainty related purely to the measurements 
(equipment, conditions and procedure) and random drifts in accelerator output. The latter 
method ii) assumes comparison of two independent output measurements. The method can be 
simplified by assuming either the same reproducibility level for the two measurements when 
the reproducibility (1SD) is obtained by deviding the obtained SD by 2 , or more cautiously 
that comparative measurements include no errors when the reproducibility is obtained directly 
from the obtained SD. 
 
Due to limited number of data points used for the model fitting, random measurement errors 
have an effect on the fitted model and the SD of the fitting errors does not necessarily 
correspond exactly to the SD of random errors (defined as measurement reproducibility). The 
correspondence between these SDs and considerations for sufficient number of data points 
needed to fit the linear model were investigated by simulating measurement reproducibility 
levels of 0.5 and 1.0 % (1SD) and by model fitting the simulated data. The estimation is for 
linear parameters changes and is provided for the output measurements, CCs and calibration 
coefficient of the CCs. These results have not been published earlier. 
 
Feasibility of constancy checks 
 
The reproducibility of the CCs was estimated from the SD of the fitting errors of the linear 
model fitted to the CC results. The obtained reproducibility includes short-term variations in 
output and in calibration of a CC device. An empirical distribution was constructed from the 
fitting errors to quantify the scatter of the CCs around the model. The reproducibility of the 
CCs was estimated for two different positioning methods of the CC devices: by using an 
optical scale of the accelerator or by using positioning lasers. 
 
A long-term stability of the CCs was estimated by quantifying the time behaviour of the 
calibration factor for each CC device. This was done by the empirical model fitting. 
 
Measurement of energy parameters 
 
Time behaviour of the PDD at the depth of 10 cm and 1020J  were determined for the reference 
FS of 10x10 cm2 at 100 cm SSD by using the empirical model fitting as described above. In 
addition, the reproducibility of the measurements was assessed for these parameters from the 
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SD of the fitting errors as described above. Default settings of the software were used for the 
data smoothing. 
 
4.2.2. Estimation of efficacy of quality control programs 
 
A method for the estimation of treatment dose variations due to output shifts  
 
A method based on MC principle was developed to assess the accuracy of total treatment dose 
(D) in external photon beam radiotherapy. The method was used to estimate the variations in 
treatment dose (∆Ds) due to shifts in output level with respect to the predefined reference 
dose (∆D = 0) achievable with the use of a QC program for output, i.e. a certain output 
measurement time interval and action levels for the output and CC measurements (Figure     
4-3). The probability that an output is outside of the predefined action levels can be estimated 
for different QC programs. The method takes into account the stability of the output and 
random errors (reproducibility) of the output measurements and the relative CCs. These are 
given in the form of empirically determined or simulated probability distributions. The 
method was accomplished with MATLABTM (The MathWorks Inc., Natick, MA). 
 
During a treatment course, an output level was assumed to change linearly and the output 
stability is generated from a distribution of linear output changes. Two different practices of 
output level adjustments were simulated: i) the ‘normal case’, when an output exceeding the 
action level is adjusted to a measured reference value; ii) the ‘anticipatory case’, when a 
rising output level is adjusted to a value below a measured reference level and a decreasing 
output level is adjusted to a value above a measured reference level. 
 
The simulation method assumes one type of output measurements making no difference 
between the definitive and routine calibrations. Both of these are carried out by using the 
same reference ionization chamber and the relation between the definitive calibrations carried 
out in a water phantom and the routine calibrations carried out potentially in a PMMA or solid 
water phantom is assumed accurate. The relation should be determined locally and the 
corresponding uncertainty should be added to the estimated overall uncertainty. 
 
The performance of relative CCs several times a week was included in the simulation. If the 
average level of the CC results exceeded the predefined check action level, an output 
measurement was carried out. The check device reading was calibrated against every output 
measurement. Therefore the error of the check calibration factor includes random errors of 
both output and CC measurements. 
 
Reproducibility of output measurements 
 
The simulations were carried out for two different levels of output measurement 
reproducibility. For the best accuracy level, random errors were generated from an empirical 
distribution with a SD of 0.7 % and a 95 % CI of - 1.4 … + 1.4 % being consistent (within 95 
% CI) for the reproducibility obtained in the Study I. Worse measurement accuracy level was 
estimated theoretically by widening the empirical distribution obtained in the Study I resulting 
in a SD of 1.4 % and a 95 % confidence interval of - 2.8 … + 2.8 % corresponding to 
estimated uncertainty of output measurements in user’s beam made by IAEA in the TRS-398 
(IAEA 2000). The empirical distribution was considered more appropriate than e.g. the 
Gaussian distribution because the empirical distribution lacks very large measurement errors 
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(> 3.6SD). Such errors occur very rarely, they are usually indentified and the estimation of 
probability for undetected large errors is uncertain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-3. The simulation of total dose (D) received in a treatment. A treatment begins at a 
random time point between two successive output measurements (denoted as OMs). A 
measured reference output level differs from the true reference level (∆D = 0) due to a 
random OM error. When ‘anticipatory’ output adjustments are used, the output level at the 
OM, carried out prior to the beginning of the treatment, is generated uniformly within the 
predefined OM action levels. In the ‘normal case’, this output level is generated uniformly 
within the upper half (e.g. [0 … +2 %]) in the case of a rising output level and within the 
lower half (e.g. [-2 … 0 %]) in the case of a decreasing output level. A linear trend assumed 
in the output during a treatment time is generated randomly from the distribution given. If the 
action level is exceeded in the subsequent OM, as is the case in this figure, the output level is 
adjusted to a measured reference level. An average treatment time of 1.5 months was assumed 
for the calculations (30 fractions). 
 
 
Reproducibility of constancy checks 
 
In the Study I, the distribution of random errors was estimated for the CCs having a SD of 0.5 
%, when the device was positioned conventionally by using an optical scale. An independent 
effect of long-term instability of ± 1 % in a year (reported recently by several manufacturers 
of the CC devices) was approximated by widening the empirical distribution resulting in a SD 
of 1.1 % and a 95 % confidence interval of - 2.1 … + 2.1 %. The investigation was limited 
within the range of output measurement intervals from 0.25 to 6 months to minimize risk of 
too optimistic estimations due to larger long-term instability than assumed here. 
 
Output stability 
 
The simulations were carried out for different levels of output stability to achieve estimations 
for different practical situations. The estimations made for linear output changes of 0, 0.3, 0.6 
and 1.2 %/month offer approaches for individual accelerators. The fully stable case (trend 
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equals to zero) was included to estimate dose errors merely due to the reproducibility of the 
QC measurements. In addition, the simulations were carried out for the distributions of linear 
output changes determined in the Study I to approach the spread of outputs more realistic 
during a long-term period for a group of accelerators. 
 
The estimation of the spread of outputs achievable by using a QC program was carried out 
cautiously by assuming that the maximal trend in the empirical data (being 1.2 %/month) is 
just within 95 % confidence interval of the range of output trends observed in practice. For the 
simulation, a Gaussian distribution of output trends with a mean of zero and a SD of 0.6 
%/month was used. 
 
Assessment of biological influence  
 
The variations of treatment doses (∆Ds) were converted into variations of TCP (∆TCPs) to 
assess biological effects related to the use of a QC program and also the other factors 
investigated in this thesis. The linear conversion was assumed sufficient due to relatively 
small ∆Ds and the ∆TCPs were obtained by using the Equation 3. A normalized steepness 
value γ  = 2.7, reported by Okunieff et al. (1995), was chosen to describe average tumor dose 
response. 
 
The dose-response characteristics of normal tissue complications are very different depending 
crucially on the realization of treatment (e.g. irradiated tissue type, organ, irradiated volume 
and dose distribution). Therefore, numerical estimations related to the NTCP included in this 
thesis concerns only the dose response of the major salivary glands in the head and neck 
IMRT (investigated in Study IV). For known dose-response steepness, however, one can 
estimate an increase in NTCP from the results presented for the ∆Ds. 
 
4.2.3. Evaluation of beam data 
 
Determination of dose calculation accuracy 
 
Dose calculation accuracy for open rectangular fields in Finnish RT centres was estimated 
from the dose measurements carried out by STUK. Difference between the measured and 
calculated dose was corrected for a shift in accelerator output level by subtracting the 
difference between the measured and reference values of output calibrations (Gy/MU). 
Therefore, the difference between the measured and calculated dose was considered to reflect 
the calculation accuracy. Possible misinterpretations due to random measurement errors were 
minimised by comparing the results obtained on at least two successive site visits within two 
years. Calculation accuracy of open rectangular fields was considered to reveal the quality of 
basic beam data used for the TPS configuration according to the Equations (9)-(10). The 
factors for the correction of different geometries used for the basic beam data and absorbed 
dose measurements (the Equations (11)-(12)) depend on the ratios of PDDs were assumed to 
give negligible contribution to calculation errors. 
 
Averaged data sets for OF and PDD 
 
For the identification of reasons for poor calculation accuracy exceeding the limit of ± 2 %, 
averaged reference data sets were constructed for both OFs and PDDs by using the data 
collected from the 9 RT centres. The local beam data were compared to the obtained averaged 
data to investigate whether potential differences explain the poor calculation accuracy. The 
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construction of averaged data sets was motivated by several investigations suggesting 
consistent values of the basic beam data for accelerators of the same manufacturer, model and 
energy (Fontenla et al. 1992, Watts 1999, Followill et al. 2004, Cho et al. 2005). 
 
Reference data sets were constructed for the OFs, defined at dmax (for each field size) 
measured at 100 cm SSD. Averaged PDD data were constructed at a 10 cm depth for data 
measured at 100 cm SSD. Only the OFs and PDDs giving high dose calculation accuracy 
within ± 1 %, fulfilling the calculation accuracy recommended for open square fields, were 
averaged to construct accurate reference data sets. PDD data were available only from five out 
of the nine centres. The presentation of averaged data requires the use of beam QI. Since 1020J  
is usually measured in clinical practice instead of 2010TPR , the accuracy of the empirical 
relation between these parameters given in the Equation (5), was estimated through 
measurements. 
 
Averaged data sets for reference MUs  
 
The number of MUs calculated by local physicists were corrected to result in accurate dose 
delivery. First, the calculated MUs were converted into normalised MUs by multiplying them 
by the output calibration factor (Gy/100 MU). These normalised MUs simply corresponded to 
the numbering of MUs required when the output is calibrated to 1 Gy/100 MU. Then, the 
normalised MUs were corrected to give an exact dose delivery of 2 Gy. This was done by 
scaling the result of the dose measurement (corrected for output level shifts) and 
correspondingly the normalised MU count. The averages of the corrected MU counts from 24 
accelerators were used for the reconstruction of averaged MU data sets. Only two Clinac 600 
Cs were excluded from the analysis due to non-standard shadow trays used in the beam. 
Basically the MUs can be considered as OFs defined at 10 cm depth in an isocenter. 
 
Parametrization of beam data 
 
The averaged OF and MU data sets were parametrised for the open square fields in order to 
present them in a compact way. A non-linear model function with an empirically determined 
form was used. 
 
In order to parametrise OFs for rectangular open fields, the feasibility of an empirical 
equivalent square field formula of (Vadash and Bjärngard 1993) 
 
 
YAX
XYAC +
+= )1(                                                                                            (15) 
 
 
obtained for head scatter factors, was evaluated, where A is an empirical parameter and C x C 
is the equivalent collimator opening for a field XxY. The combinations with X,Y = 5, 10, 15, 
20 and 35 cm were used to determine A. 
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4.2.4. Estimation of accuracy requirements based on dose response 
 
Modelling of dose response 
 
Volume based (Lyman) normal tissue complication probability model (Lyman 1985) was 
chosen for the describtion of salivary gland function after RT. Mean dose (Dmean) within a 
gland was chosen as a dosimetric measure for the biological effect since parotid glands have 
been shown to behave like parallel organs (Eisbruch et al. 1999). The ratio (rEF) of EF values 
obtained for a gland before (t = 0) and 6 months after RT was assumed to follow sigmoidal 
dose response relationship as  
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where D50 and Γ are fitting parameters. The data obtained for the parotid and submandibular 
glands were combined since no significant differences have previously been observed in the 
dose response characteristics of these glands by using the rEF as an endpoint (Tenhunen et al. 
2008). In addition to the sigmoidal dose response model, a linear model was fitted to the data 
points forming the steepest slope region. 
 
Estimation of dosimetric and geometric accuracy requirements 
 
To predict rEF at an accuracy level considered clinically significant, ∆rEF = ± 0.1, analogous 
to ∆NTCP = ± 10 %, was chosen. Accuracy criterion for Dmean was estimated by using the 
maximal slope of the obtained sigmoidal dose response curve. The criterion of Dmean was 
converted into geometric accuracy requirement by using the average 3D dose gradient value 
within the glands separately for the parotid and submandibular glands. 
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5. RESULTS 
 
 
5.1. ANALYSIS OF QUALITY CONTROL MEASUREMENTS 
 
5.1.1. Observed time trends 
 
Short-term output 
 
The obtained probability distributions for linear short-term output trends are presented in 
Figure 5-1. The output was observed to increase with time for the Clinac 2100 C/CDs and to 
decrease for the Clinac 600 C/CDs. Only very shallow negative output trends were observed 
for the Clinac 2100 C/CDs. The steepest trends were about 1 %/month for both high and low 
photon energy regions, and were observed for new accelerators just after commissioning. 
During the observation period 3 new accelerators were commissioned. High probability for 
very shallow trends demonstrates the tendency of the outputs to stabilize with time. 
 
 
Figure 5-1. The empirical probability distributions of linear short-time output trends 
constructed from the quality control data collected for 6 MV (black bars) and for 15-18 MV 
(white bars). For 6 MV, the mean ± SD of the output trends, weighted by their relative 
durations, were 0.05 ± 0.27 %/month. For 15-18 MV, the corresponding values were 0.15 ± 
0.19 %/month. 
 
Long-term output 
 
The time behaviour of output was highly individual and depended on the age of the 
accelerator (Figure 5-2). An exponential model of form 
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was empirically found suitable for non-linear outputs, where a´´, b´´ and c´´ are the fitting 
parameters. The exponential model was preferred only for 2 new accelerators with long 
observation time (≥ 40 months). The linear model was sufficient for new accelerators or 
monitor chambers with short observation time (≤ 21 months) and for older accelerators. More 
detailed results of the long-term output modelling are summarized in Study I (Table 1). 
Maximal fitting errors of the preferred long-term output models ranged normally from 0.1 to 
1.0 % with a mean of 0.7 %. The results of three output measurements (2.4 % of the total) 
were clearly outlying (1.2, 1.4 and 2.1 %) from the time trends formed by other output 
measurements and CCs due to unknown reasons. 
 
 
 
 
Figure 5-2. Systematic cumulated long-term drifts in output levels. Accelerators with sealed 
monitoring chambers: a) Example of both an exponentially increasing level (output 
measurements illustrated with squares) and a linearly decreasing level (output measurements 
illustrated with triangles). The proposed models (solid lines) describe well the constructed 
drifts. An accelerator with an unsealed monitoring chamber: b) According to CCs (stars with 
a solid line) and output measurements (squares with a dashed line), a periodic behaviour 
(period about a year) due to environmental conditions was observed. Differences between the 
output and CC measurements increase significantly with time demonstrating great systematic 
long-term drift in the stability of the CC device (regular recalibrations removed). It should be 
reminded that the constructed output drifts do not describe dose errors in treatments because 
of dose adjustments. 
 
 
The average time for an output drift of 2 %, corresponding to the most commonly used action 
level for the output measurements, was 18 ± 12 months (averaged for the beams listed in 
Study I, Table 1). The non-linearly changing outputs of 2 new accelerators showed steep 
upward trends just after commissioning reaching the drift of 2 % even within 2 - 3 months. 
The nonlinear outputs stabilized essentially during the first two or three years. 
 
With one Clinac 600 CD, one time period was excluded from the long-term modelling 
because the quantitative determination of output trends was greatly uncertain due to frequent 
dosimetrically significant repairs and adjustments (magnetron replacements, adjustment of 
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beam energy and dose rate). During this period, the CCs indicated exceptional output 
behaviour being both greatly increasing and decreasing. Before and after this period, however, 
the output was again decreasing and could be modelled, consistently with the other 600 CDs. 
 
Unfortunately, only short data sets were collected for an accelerator with unsealed monitor 
chamber (SL 18) because of multiple monitor chamber and magnetron replacements during 
the observation period. These data sets indicated periodic output behaviour due to 
environmental conditions (humidity) with amplitude of about 1 %. The effect seems to limit 
the accuracy of output modelling and prediction of output level for accelerators with unsealed 
monitor chambers. 
 
Stability of constancy checks 
 
The calibration factors of two out of the four CC devices increased linearly during the whole 
observation period (1-3 years) at the rate of 0.30 ± 0.08 %/month and 0.29 ± 0.04 %/month 
for 6 MV and 15-18 MV, respectively, (correlation coefficient |ρ| > 0.95). The effect of the 
drift in the calibration is demonstrated in Figure 5-2 b). The calibration factors of the rest two 
devices remained constant with time (|ρ| < 0.7). The SD of the relative fitting errors of the 
linear models was 0.6 %. 
 
Beam energy parameters 
 
The energy parameter 1020J  was constant (|ρ| ≤ 0.5) for all the beams during the observation 
period. Consistently, the PDD at 10 cm depth for the reference field was constant (|ρ| ≤ 0.7). 
 
5.1.2. Reproducibility of measurements 
 
Output measurements 
 
The SD of the differences between the comparative measurements of the hospital and STUK 
was 0.37 % resulting in a rough estimation for the reproducibility of the local output 
measurements carried out at the depth of 10 cm. By incorporating the uncertainty of the PDDs 
measured at the 10 cm depth being 0.30 %, the estimated reproducibility of the local output 
measurements becomes about 0.5 % at the dmax. 
 
The SDs of the fitting errors of the long-term output models were 0.4 and 0.5 % for 6 and 15-
18 MV, respectively. According to the simulation of random measurement errors, the 
estimation of output measurement reproducibility from the SD of the fitting errors results in 
systematic underestimation depending on the number of data points used to fit the models. For 
10 data points, as was the case on the average in the current analysis, the underestimation is -
0.05 ± 0.12 % and -0.09 ± 0.23 % for measurement reproducibility levels of 0.5 % and 1.0 % 
(1SD), respectively. By considering these, the estimated uncertainty of the local output 
measurements becomes about 0.5 ± 0.2 % when presented with 95 % CI. Importantly, the 
both included methods resulted in consistent values for the reproducibility of the local output 
measurements. 
 
If accuracy level of 0.1 % is desired for the determination of measurement reproducibility, 
many fitted data sets with minimal number of included data points of 10 are needed. The 
importance of the number of data points used for a modelled data set is emphasized by 
realizing that for 5 data points the underestimation of the reproducilibity is significantly 
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greater, being -0.10 ± 0.17 % and -0.20 ± 0.33 %, for measurement reproducibility levels of 
0.5 and 1.0 %, respectively. 
 
Constancy checks 
 
The reproducibility of the CCs was 0.5 % when the device was positioned conventionally by 
using optical scale while it was improved to 0.2 % when the device was positioned by using 
lasers. The obtained distributions of random CC measurement errors are presented in Study I 
(Figure 4). Comparison of these values suggests that the reproducibility of the CCs is 
predominated by random distance errors of the positioning of a device. 
 
The uncertainty of a CC calibration factor includes the uncertainties of both output and CC 
measurements and two successively determined calibration factors differed often more than 1 
% from each other (Figure 5-3). Therefore an output trend can be determined best by using 
the same calibration factor or by using the readings of a device instead of calibrated values.  
 
Beam energy parameters 
 
The SD of the measured PDDs at a 10 cm depth for the reference 10x10 cm2 field was 0.3 ± 
0.1 %, ranging from 0.2 to 0.4 % for individual accelerators. The SD of the 1020J s was 0.5 ± 
0.2 %, ranging from 0.2 to 0.7 %. The SD of dmax was 0.5 ± 0.2 mm for 6 MV and 1.2 ± 0.3 
mm for 15-18 MV. It should be realized that these values depend on smoothing method used 
for the measured data. 
 
5.1.3. Methods proposed for quality control 
 
The proposed single-exponential and linear models described normally (without 
dosimetrically significant malfunctions, adjustments or repairs) well the constructed 
systematic long-term drifts in output while linear model was sufficient for short-time drifts. 
The proposed methods proved well suited for the estimation of parameter changes and 
measurement reproducibility. The model fitting of the QC results seems to facitate the 
regognition of outlying measurements reducing the number of unnecessary adjustements of 
output level. 
 
The determination of systematic drift in CC device reading is crucial in the confirmation of a 
good clinical dose control and in the determination of output trends according to the CCs. The 
robustness of the CC calibration seems to be improved by comparing a newly obtained 
calibration factor to a value determined by model fitting of the previous values (Figure 5-3). 
For this ‘predicted’ value, the effect of random errors is minimized (provided that enough data 
is fitted) and thus the comparison may reveal the cases when the level of the CC results would 
‘jump’ away from a true output level due to an erroneous calibration factor. The accuracy of 
the calibration factor may not necessarily be improved by simply averaging the previously 
determined values because a device reading may drift systematically with time. 
 
The result of an output measurement could usually be estimated within 0.5 % from the 
previous measurement by using the output trend determined by fitting a linear model to the 
CC results (with systematic long-term drift in device reading taken into account). This offers 
approach for estimation of individual time intervals for output measurements. The approach is 
independent of the uncertainty of the calibration factor of a CC device. 
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Figure 5-3. The calibration factors obtained for a CC device in connection with output 
measurements. The values are given as differences from the average value. The original 
values are indicated with ‘x’s, while the squares indicate the obtained values when random 
errors of both output and CC measurements are estimated and corrected. The errors were 
estimated by using the proposed output modelling and by averaging the first 5 check readings 
after the calibration, respectively. Large random errors exceeding ± 0.6 % (1SD, horizontal 
dashdotted lines) in some calibration factors (the 1st and 3rd ‘x’ from the left) were also 
recognized by fitting a linear model (solid line) to the obtained (uncorrected) calibration 
factors demonstrating the usefulness of empirical model fitting. 
 
 
 
5.2. EFFICACY OF QUALITY CONTROL PROGRAMS 
 
Achievable deviation of outputs 
 
For a given QC program, the 95 % and 99 % CI limits of ∆Ds were similar for all the included 
distributions of output variations. In contrast, for single output trends, great dependence on 
the steepness of a trend was observed showing that the average of output variations has more 
prominent effect than their deviation. The limits for the measurement interval of 3 months 
were usually about two times as large as those estimated for the interval of 1 week. The effect 
of output stability on the ∆Ds practically vanished when the measurements were carried out 
weekly and outputs could be kept within a spread defined by the action levels.  
 
In the case of the steepest observed output trends of up to 1.2 %/month, the use of the 
measurement interval of 3 months and action level of ± 2 % kept an output practically within 
about ± 4.0 % or ± 5.5 % (99 % CI) for the measurement reproducibility level of 0.7 % or 1.4 
%, respectively. By using the interval of 1 month, these limits were about ± 3.0 % or ± 4.0 %, 
respectively. The probability of steep output changes is normally very small and they are 
detected by the CCs and, therefore, the output is kept within narrower limits as estimated in 
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this ‘worst case scenario’. All the presented 95 and 99 % limits of the ∆Ds are one-directional 
(in the direction of trend). 
 
The effect of use of different action levels is demonstrated in Figure 5-4. Because the 
included distributions of output changes gave quite similar results, it is most likely that these 
95 % limits provide generally feasible long-term estimations for the ∆Ds. Results for linear 
output trends are presented in the Study II (Table 1). 
 
The effect of anticipatory adjustments for output levels was relatively small on the 95 and 99 
% limits of the ∆Ds. By using such adjustments, the limits could be reduced only by about 0.3 
% when a measurement interval from 1 to 3 months was used and the measurement 
reproducibility was 0.7 %. If measurement reproducibility was 1.4 %, these limits could be 
reduced by about 0.4 %. 
 
For the empirical distributions of output variations, the SD of ∆Ds was about 1.5 %, 1.1 % 
and 0.8 % for the measurement intervals of 3, 1 and 0.25 months, respectively, when the 
output measurement reproducibility was 0.7 %. For the theoretical Gaussian distribution of 
output variations together with measurement reproducibility of 1.4 %, the use of these 
measurement intervals resulted in the SD of about 2.0 %, 1.4 % and 0.9 %, respectively. 
 
 
 
 
Figure 5-4. The upper 95 % limit of ∆Ds estimated for empirical distribution of linear output 
changes determined for the 15-18 MV beams. The estimations were carried out for the output 
measurement reproducibility levels of a) 0.7 % and b) 1.4 %. The action levels of the QC 
measurements are expressed in the figures as:  ± OM %, ± CC %, where OM is the action 
level for the output measurements and CC is that for the constancy checks. ‘Normal’ practice 
of output adjustments was assumed, where output is adjusted to a measured reference value. 
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Probability of unacceptable treatments 
 
The probability of unacceptable treatments (defined as |∆D| > 2 % due to output shifts) 
achievable with the use of a QC program is summarized in Study II (Table 2) for different 
levels of output stability and measurement reproducibility. The probabilities depended 
crucially on both the output stability and the reproducibility of the output measurements. The 
fraction of unacceptable treatments could be significantly decreased by using anticipatory 
adjustments for output. 
 
The influence of different combinations of output measurement time intervals and action 
levels are demonstrated in Figure 5-5. The presented curves have the greatest gradients when 
measurement interval is between 0.25 and 2 months, since the random errors of the QC 
measurements become more prominent when the number of output measurements during a 
treatment time decreases.  
 
It was observed that the probability of unacceptable treatments remained equal when the time 
interval for the output measurements was doubled and the action level for the output 
measurements was lowered from ± 2 % to ± 1.5 % and the action level for the CCs from ± 3 
% to ± 2 %. Moreover, the measurement interval of 3 months could be doubled to 6 months if 
merely the action level of the CCs was lowered from ± 3 % to ± 2 %. In these cases, the 
spread of output (99 % limit of ∆Ds) widened about 0.4 % or 0.7 % when the output 
measurement reproducibility was 0.7 % or 1.4 %, respectively. The use of slightly relaxed 
action level of ± 2.5 % for the output measurements increased the probability of unacceptable 
treatments to the level achievable by using a doubled output measurement time interval. 
 
 
Figure 5-5. The probability of unacceptable treatments with ∆D > + 2 % estimated for the 
empirical distribution of linear output trends determined for the 15-18 MV beams. The 
estimations were carried out for the output measurement reproducibility levels of a) 0.7 % 
and b) 1.4 %. The action levels of the QC measurements were expressed in the figures as: ± 
OM %, ± CC %. ‘Normal’ practice of output adjustments was assumed. 
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The 95 and 99 % limits of the ∆Ds and the probabilities of unacceptable treatments are more 
practical measures for achievable dose accuracy than the SDs of the ∆Ds. This is because the 
SDs may be small for single output trends but the mean of ∆Ds may be considerable different 
from zero. Biological risks related to tumour recurrence or normal tissue complications, 
related to the use of a QC program for output, can be assessed from the results presented in 
this chapter. 
 
 
5.3. ACCURACY OF BEAM DATA 
 
5.3.1. Finnish survey 
 
The differences between measured and calculated central axis dose are summarized for the 
Finnish RT centres in Figure 5-6. For all the test fields, the fraction of fields with a delivered 
dose within ±1, ±2 and ±3 % was 79, 97 and 99 %, respectively. For the elongated rectangular 
field of 5x30 cm2, a systematic underdosage of about -0.8 % was observed and the fraction of 
fields with a delivered dose within ±1, ±2 and ±3 % was 63, 96 and 100 %, respectively. For 
the worst observed cases, calculation accuracy could be improved by 2-3 % when compared 
to the most accurate dose calculations observed. The results of the centres are summarized in 
detail in Study III (Table 1). 
 
The measured and calculated dose agreed within +1 % in all test fields for 7 (25%) and 6 
(30%) of the 4-6 MV and 10-18 MV beams, respectively. The limit +1 % was exceeded only 
for the 40 x 40 cm2 field or the extremely elongated fields (5x30 cm2 or 30x5cm2) for 8 (29%) 
and 6 (30%) of the 4-6 MV and 10-18 MV beams, respectively. A tolerance of ± 2 % was 
exceeded at least in one test field for 4 out of the 28 investigated beams of 4-6 MV (14 %) 
and for 2 out of 20 beams of 10-18 MV (10 %).  
 
 
 
 
Figure 5-6. The difference between measured and calculated central axis dose at a 10 cm 
depth for the open test fields. a) The distribution of differences for all fields (N=403). The 
mean ± SD were -0.2 ± 0.9 %. b) The distribution of differences for elongated rectangular 
fields of 5x30 cm2 (N=48). The mean ± SD were -0.8 ± 0.9 %. 
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5.3.2. Method proposed for quality control 
 
Consistency and parametrization of beam data 
 
The numbers of MUs corrected to result in correct isocentric dose delivery of 2 Gy at a depth 
of 10 cm (100 cm SAD) for the open square fields were equal within ± 1.0 % for all the 24 
accelerators included. A non-linear function of form 
 
 
dcX
baXh
)(
)( −+=                                                                                                  (18) 
 
 
was empirically found suitable (accuracy within ± 0.3 %) for the parametrisation of the 
averaged MUs, where a,b,c and d are the fitting parameters, and X is the side of a square field 
given in cm. The fitting parameters for FS ranging from 5x5 to 40x40 cm2 are presented in 
Study III (Table 2). The SD of the MUs was ≤ 0.6 % for the most FSs. 
 
Where the agreement between measured and calculated dose was within ± 1 %, the OFs of the 
open test fields measured by the centres were in good agreement (within ±0.7%) with the 
averaged values. The parametrisation of the averaged OFs defined at dmax for the open square 
fields ranging from 4x4 to 40x40 cm2 is presented in Study III (Table 3). The Eq. (18) was 
used (accuracy within ± 0.3 %). 
 
Where the agreement between measured and calculated dose was within ± 1 %, the PDDs of 
the test fields measured by the centres were in good agreement (relative difference within 
±1.2%) with their averaged values. The averaged PDDs are presented in Study III (Table 4). 
The PDDs showed about two times larger maximal deviation than the OFs. Due to relatively 
large deviation and scarcity of the PDD data provided, the averaged PDDs were published 
only for nominal energies with several investigated beams. Since the empirical relationship 
between 1020J and 
20
10TPR  (Equation 5) was experimentally found to be accurate within ± 0.1 % 
for the investigated beams (except ± 0.3 % for 1020J  = 1.712), the 
20
10TPR values for the beams 
were calculated by using this equation. 
 
In the cases of good calculation accuracy within ± 1 %, the OFs for rectangular fields XxY at 
dmax could be determined for nominal energies 4, 6, 10 and 15 MV by using the equivalent 
square field relation (Eq. 15) with a maximal error of 0.7 % (SD ≤ 0.3 %). This accuracy was 
achieved for the Clinac 600 CDs and 2100 CDs by using A values of 1.31 and 1.53, 
respectively. The values of A depended on the accelerator model and not on the nominal 
energy. For 18 MV beams from Clinac 2100 CDs, the best value for A was also 1.53 but the 
maximal error increased to about 1.1 % (SD ≈ 0.4 %). The SD of the A values was ≤ 0.05 for 
all nominal energies. The number of the accelerators investigated is shown for each nominal 
energy in Study III (Table 3). 
 
The use of reference data in identification of reasons for calculation disagreements 
 
For two 6 MV and two 15 MV beams having maximal dose calculation error of about 3 %, 
the OFs used for the TPS deviated maximally by about 2.5 and 1.5 %, respectively, from the 
obtained averaged OFs (Figure 5-7). The correlation between the deviation and the error was 
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0.31 and 0.90 for the 6 and 15 MV beams, respectively. When the OFs were replaced by the 
averaged data, the maximal calculation errors decreased to about 2 % for all the four beams. 
For these beams, also the PDDs used for the TPS deviated maximally by about 2 % from the 
obtained averaged PDDs. The correlation between the deviation and the calculation error was 
0.95 and 0.99, respectively. When also the PDD data were replaced by the averaged data, 
maximal calculation errors decreased to about 1 % for all the four beams, revealing the 
existence of significant errors in beam data. 
 
For one 6 MV beam of Clinac 600 CD, dose calculation errors of up to about 3 % were 
observed. The TPS was configured by using OFs measured for a 6 MV beam of Clinac 2100 
CD. The average OFs of 2100 CDs differed from those of 600 CDs maximally by about 2.2 % 
(even when the beam energy parameters were equal) explaining the observed calculation error 
(|ρ|=0.97). 
 
For one 6 MV beam of Clinac 2100 CD, calculation error of 2.3 % was observed for the 
40x40 cm2 field. The OFs used for the TPS configuration were consistent with the averaged 
data within 0.3 % while the PDD data deviated from the averaged data for that field size by 
about 2.4 % explaining the observed calculation error. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-7. The OFs at dmax (‘x’s with solid lines) measured for the 6 MV beams of Clinac 
2100 CDs. One set of OFs (triangles with dashed line) deviated maximally by about 2.5 % 
from the obtained averaged OFs (squares with solid line). The large deviations were related 
to large calculation errors for central axis dose. 
 
 
5.4. SET-UP ACCURACY 
 
Set-up errors and their effect on glandular mean dose 
 
Summary of patient set-up variations is presented in Table 1. SD of random errors ranged 
from 0.4 to 3.3 mm among the patients. The shifts of Dmean values due to systematic set-up 
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errors are summarized in Table 2. Mean ± SD of 3D dose gradients within the parotid glands 
(defined as dDmean/dr) was 0.8 ± 0.3 Gy/mm (range from 0.2 to 1.7 Gy/mm) in the steepest 
gradient direction toward a gland (usually anterior, cranial and lateral). The corresponding 
gradient within the submandibular glands was 0.9 ± 0.6 Gy/mm (range from 0.1 to 2.3 
Gy/mm). No significant correlation was found between the gland volume and ∆Dmean or dose 
gradient (|ρ| ≤ 0.42). 
 
 
Table 1. Summary of patient set-up variations. The results are in millimetres and are 
expressed as mean ± SD calculated for all 25 included patients. 
Direction 
Shift type A-P   C-C  LAT   |A-P|   |C-C|   |LAT|   3D 
Systematic 
 
Random 
0.5 ± 2.2 
 
0.0 ± 1.5 
1.1 ± 2.1 
 
0.0 ± 1.4 
0.1 ± 1.9 
 
0.0 ± 1.4 
1.7 ± 1.3 
1.1 ± 0.9 
1.9 ± 1.4 
1.1 ± 0.9 
1.5 ± 1.2 
1.1 ± 0.9 
3.4 ± 1.6 
 
2.2 ± 1.1 
Directions: A-P = anteroposterior (+ = posteriorly), C-C = craniocaudal (+ = caudally),  
LAT = lateral (+ = to right).  
| | denotes absolute values or magnitudes of shifts. 
 
 
Table 2. Shifts of the glandular Dmeans due to the observed systematic patient set-up 
variations. The results are given as mean ± SD for the glands and the range is in parenthesis. 
Gland  Planned 
 Dmean (Gy) 
  Shifted    
 Dmean(Gy) 
  Shift 
  (Gy) 
 |Shift| 
     (Gy) 
  Shift 
       (%) 
  |Shift| 
    (%) 
Parotids 
(N=41) 
 23.2 ± 6.5 
(13.8...55.2) 
22.3 ± 7.1 
(11.5...56.2) 
-0.8 ± 1.6 
(-4.5...2.9) 
1.4 ± 1.2 
 (0...4.5) 
-4.3 ± 8.3 
 (-25...15) 
6.7 ± 6.4 
 (0...25) 
Subm. 
(N=17) 
 33.8 ± 11.3 
(22.6...55.1) 
33.5 ± 11.1 
(22.1...52.5) 
-0.3 ± 2.7 
(-8.0...3.9) 
1.9 ± 1.9 
 (0...8.0)  
-0.3 ± 8.2 
 (-20...17) 
6.0 ± 5.5 
 (0...20) 
Both 
(N=58) 
 26.3 ± 9.4 
(13.8...55.2) 
 25.6 ± 9.8 
(11.5...56.2) 
-0.7 ± 2.0 
(-8.0...3.9) 
1.5 ± 1.4 
 (0...8.0) 
-3.1 ± 8.4 
(-25...17) 
6.5 ± 6.1 
 (0...25) 
The shift is defined as shifted – planned dose value obtained for a gland. 
| | denotes absolute values or magnitudes of the shifts. 
 
 
Dose response parameters  
 
The relative ejection fraction of a major salivary gland as a function of the planned Dmean is 
presented in Figure 5-8. The 95 % confidence intervals of the parameter fits are presented in 
the figure. The maximal slope of the sigmoidal model was -0.041 1/Gy. In the form of 
normalized slope this is γ  = - 0.041 1/Gy * 30.4 Gy = 1.2. Dose region for the fitting of the 
linear model was 10…40 Gy but equal slope value was obtained by using a narrower region 
20…40 Gy. 
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Estimation of dosimetric and geometrical accuracy requirements 
  
The accuracy criterion of ±10 % for the rEF results in an accuracy criterion of ± 2.4 Gy for 
Dmean of both the parotid and submandibular glands. Cautious criteria for 3D shifts can be 
achieved by considering positional shifts only in the most critical dose gradient direction 
(shift in all three directions toward a gland). On the average, the above accuracy requirement 
of Dmean was achieved with maximal systematic 3D shift of 3.0 mm for the parotid glands and 
of 2.7 mm for the submandibular glands. 
 
 
                                                                          
Figure 5-8. The dose response models (solid lines) for the relative ejection fraction (rEF) of 
the major salivary glands 6 months after radiotherapy. Squares are the means of the rEFs for 
four subgroups of equal sizes with 95 % confidence limits of the means presented. a) The 
sigmoidal model and b) the linear model (fitted to a narrower range of data points between 
10...40 Gy). The sizes of the subgroups were n = 58/4 = 14…15 and n’ = 53/4 = 13…14, 
respectively. 
 
 
 
5.5. ACHIEVABLE IMPROVEMENT IN DOSE ACCURACY 
 
5.5.1. Effectiveness of the investigated factors 
 
The efficacy of the proposed empirical model fitting of the QC measurement results in the 
reduction of the uncertainty related to random measurement errors is summarized in Table 3. 
The presented results are applicable for the output and CC measurements and for the 
calibration coefficient of a CC device. The benefit of the modelling depends on the number of 
data points used for the fit. 
 
The uncertainties estimated for the factors investigated in this thesis and the efficacy of the 
proposed methods, suggestions and criteria in the reduction of these uncertainities are 
summarized in Table 4. Two aspects of improvements are presented: i) those based on the 
reduction of SD indicate reduction of uncertainty observable in national and international 
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multicentre comparisons and increase in the consistency of treatment quality, ii) those based 
on the reduction of maximal errors indicate the benefit obtainable for individual patients and 
improvement in consistency of treatment quality. 
 
 
Table 3. Uncertainty (1SD) (%) of a current measurement result when its value is obtained 
from the linear model fitted to the results of the current and previous measurements. The 
uncertainty (1SD) (%) estimated for a current measurement result when its value is 
predicted by fitting the linear model to the results of the previous measurements (in italics). 
Number of data points used to fit the model Measurement  
reproducibility (1SD) (%)   5    10    15  30 
0.50 0.39 0.29 0.24 0.18 
1.00 0.77 0.58 0.49 0.36 
0.50 0.53 0.34 0.27 0.19 
1.00 1.05 0.68 0.54 0.38 
The results are indepent of the steepness of a linear time trend and the length of equal time 
intervals between the measurements. 
 
 
The improvements for the reproducibility of the output (OM) and constancy check (CC) 
measurements and the calibration coefficient of a CC device are presented for typical size of 
data sets achievable for the model fitting of QC measurements consisting of ≥ 10 data points. 
The maximal effects are based on special cases observed in the analysis of QC data such as 
outlying output measurements and CC calibration factor. Maximal effect of systematic long-
term drift in stability of a CC device is calculated for output measurement time interval of 3 
months used widely in Finland. 
 
 
Table 4. Summary of the uncertainties estimated for the investigated factors, the proposed 
improvements and their effects. 
   SD (%)  
Investigated factor 
 
Improvement Estimated Improved 
Maximal  
effect (%) 
Reproducib. of OMs Model fitting 0.5 0.3 ≈ 21 
Reproducib. of CCs Model fitting 0.5 0.3 ≈ 21 
Calibr. coeff. of CCs Model fitting 0.6 0.4 ≈ 21 
Drift in CC stability Model fitting  -   - ≈ 11 
Beam data Accuracy criterion of ±1 % 0.9 0.6 ≈ 21 
QC program Interval from 3 to 1 month2 1.5 1.1 ≈ 1 
QC program Interval from 1 to 0.25 month2 1.1 0.8 ≈ 1 
QC program Lowering of action levels3 ∆SD = -0.3 ≈ 0.5 
Output adjustments Normal -> anticipatory ∆SD = -0.2 or -0.14 ≈ 0.3 or 0.24
Glandular mean dose Correction of positional shifts5 ∆SD ≈ -8.4 ≈ 25 
1Improvements observed for special cases (see text), the effect is not necessarily general. 
2Shortening of OM time interval from 3 months to 1 month or from 1 month to 1 week. 
3Lowering of OM action level from ±2 % to ±1.5 % and CC action level from ±3 % to ±2 %. 
4For OM time interval of 3 months or 1 month, respectively. 
5Correction of all systematic positional shifts based on bony landmarks near the glands. 
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The improvement of SD for central axis beam data is taken from the SD of uniform 
distribution between the limits of the proposed accuracy criterion (from -1.0 to 1.0 %). The 
maximal effect is taken from the difference between the largest observed calculation errors for 
the test fields in Finland and the limits of the proposed accuracy criterion. 
 
The presented maximal effect related to the shortening of output measurement time interval is 
within ± 0.4 % with the maximal effects (99 % limits) obtainable for the steepest output 
trends and the empirical distributions of output trends, and it is for the commonly used action 
levels of ± 2% and ±3% for the output measurements and the CCs, respectively, and for the 
output measurement reproducibility of 0.7 %. For the lower output measurement 
reproducibility level of 1.4 %, the corresponding maximal effect is 1.5 %. The improvements 
of the SDs are presented for output measurement reproducibility of 0.7 % and for the 
empirical distributions of output trends. For output measurement reproducibility of 1.4 %, the 
corresponding estimated values are 2.0 and 1.4 %, while the improved values are 1.4 and 0.9 
%, respectively. 
 
The presented maximal effect related to the lowering of the action levels is for the both output 
measurement reproducibility levels and the investigated range of output measurement time 
intervals, and it is within ±0.2 % with the maximal effects (99 % limits) obtained for the 
steepest output trends and the empirical distributions of output trends. The presented 
improvement of the SD is for the output measurement reproducibility of 0.7 % and 
measurement time intervals of 3 months and 1 month while that for the interval of 1 week is -
0.2 %. The corresponding improvements of the SDs are 0.1 % lower for the output 
measurement reproducibility level of 1.4 %. 
 
The improvements of SD and the maximal effects (99 % limits), when the type of the output 
adjustments is changed from normal to anticipatory, were estimated for the commonly used 
action levels of ±2 % and ±3 % for the output measurements and the CCs, respectively, and 
for the output measurement reproducibility of 0.7 %. The corresponding improvements of SD 
and the maximal effects were 0.1 % lower and 0.2 % greater, respectively, for the 
measurement reproducibility level of 1.4 %. For the output measurement interval of 0.25 
month, the improvements were negligible. 
 
For the major salivary glands, the maximal effect achievable for the ∆Dmean and its SD by 
correcting all systematic positional shifts based on bony landmarks is presented in the Table 
4. For the conventional strategy correcting systematic 1D shifts > 3 mm (to 3 mm), the 
remaining shifts of the Dmeans were -2.8 ± 7.6 %. 
 
5.5.2. Effectiveness of the proposed model fitting 
 
The proposed model fitting of the QC measurement results facilitates regognition of random 
measurement errors and reduction of their effect improving measurement reproducibility and 
offering possibility to lower action levels. The deviation of total doses achievable is presented 
in Table 5. The results were obtained for output measurement reproducibility of 0.4 % (1SD) 
by improving the previously used value 0.7 % by about 40 % according to the results 
presented in Table 3. The uncertainty of the calibration coefficient of the CCs was 0.6 % 
(1SD) obtained by assuming that its value is predicted cautiously through model fitting to 
short data point sets to correct its value for long-term drifts in device stability (but resulting in 
no improvement in the reproducibility according to the results presented in Table 3). The SDs 
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were calculated by using the empirical distribution of output changes obtained for 6 MV and 
the limits by using the steepest observed output trends. Further improvement achievable by 
using anticipatory output adjustments is only about 0.1 % for the presented 95 and 99 % 
limits, regardless of output measurement time interval. The results are accurate for linear 
changes in output and calibration coefficient of the CCs providing theoretical maximal effect 
that can be approached in practice. 
 
If the model fitting of the QC measurements is not used, the presented results are applicable 
when the measurement reproducibility level is 0.4 % (1SD) for the output measurements and 
0.5 % (1SD) for the CCs, provided that potential systematic long-term drifts of a CC device 
are known and their effect corrected. If the model fitting is used only for the regognition of 
outlying measurements, conformed by remeasurements, the action levels may be lowered and 
the presented result can be approached when reproducibility level is close to 0.5 % (1SD) for 
the both output and CC measurements, provided that long-term drifts of a CC device are 
known and corrected. 
 
  
Table 5. Deviation of total doses achievable by using the proposed model fitting of the QC 
measurement results in the case of normal output adjustments. The SD, 95 % limit and 99 % 
limit are presented for different action levels. The results for the case of anticipatory output 
adjustments are given in brackets. 
Action levels: ±output measurements, ±CCs 
±2 %, ±3 %  ±1.5 %, ±2 %  ±1 %, ±2 % 
  
Output 
measurement 
time interval 
(month)    SD 95 % 99 %     SD 95 % 99 %      SD 95 % 99 %
6 1.6 (1.3) 2.8 3.3  1.2 (1.0) 2.0 2.5  1.0 (0.9) 2.0  2.4 
3 1.4 (1.2) 2.7 3.2  1.1 (0.9) 2.0 2.4  0.9 (0.8) 2.0  2.4 
1 1.1 (1.0) 2.2 2.6  0.9 (0.8) 1.7 2.0  0.6 (0.6) 1.4  1.8 
0.25 0.9 (0.9) 1.5 1.7  0.7 (0.6) 1.2 1.4  0.4 (0.4) 0.9  1.0 
 
 
The results suggest that the 95 and 99 % limits of the shifts in total doses obtainable by using 
a short output measurement time interval of 1 or 0.25 month, are achievable by using 
significantly longer measurement intervals of 6 months or 1 month, respectively. 
Consistently, the SD of dose spread obtainable by using a short measurement interval of 1 or 
0.25 month is achievable by using significantly longer interval of 6 or 3 months, respectively, 
being mainly due to the lowering of action levels. On the other hand, the uncertainty of total 
doses achieved by using a certain measurement time interval can be reduced up to about half. 
Reduction of 99 % limit is about 2.5, 2.0, 1.0 and 1.0 % for the measurement interval of 6, 3, 
1 and 0.25 months, respectively. 
 
5.5.3. Combined improvement in dose accuracy 
 
Maximal improvement 
 
Maximal (99 % CI) error of dose related to the use of a dosimetric QC program and accuracy 
of basic beam data is presented in Table 6. The errors due to beam data and long-term drift in 
CC stability are systematic and they are summed linearly to the 99 % limit of the ∆D related 
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to the use of a QC program. Considerable maximal dose errors can be seen. Maximal 
improvement of dose accuracy achievable by choosing the strictest accuracy level is 9.7%-
2.0% = 7.7% when compared with the worst case presented. Considerable improvements of 
about 3…5 % can be achieved with reasonable effort by using output measurement time 
interval of 3 months if the proposed model fitting is used and effort is made for accurate beam 
data measurements. Poor accuracy of beam data renders the effort made on frequent workfull 
output measurements meaningless. 
 
Relative work load was estimated by assuming similar types of output measurements (water 
tank or solid phantom). No work load was defined for beam data measurements since they are 
not carried out regularly. Work/quality-ratio was calculated by multiplying work load and 
total ∆D. Both of these were normalized to those obtainable by using measurement interval of 
0.25 month. 
 
 
Table 6. Maximal combined error of dose (99 % limit of ∆D) allowed by different dosimetric 
QC programs and quality of central axis beam data. 
Action levels: ± OMs,  
                       ± CCs 
 
 
 ± 2 %, 
± 3 % 
 
 
± 1.5 %, 
± 2 % 
 ± 1 %,
± 2 % 
Meas. interval (month) 3 3 1 0.25 6    0.25 
Reproducibility (%) 0.7 1.4 0.7 0.7 0.41    0.41 
∆D due to output (%) 4.2 5.4 2.9 1.9 2.5    1.0 
∆D due to beam data (%) 1.0…3.3 1.0…3.3 1.0…3.3 1.0…3.3 1.0…3.3    1.0…3.3
Drift in CC stability (%) 1 1 0.3 0 corrected   corrected
Total ∆D (%) 6.2...8.5 7.4…9.7 4.2…6.5 2.9…5.2 3.5…5.8    2.0…4.3
Relative work load (%) 8.3 8.3 25 100 4.2    100 
Relative work/quality (%) 18…24 21…28 36…56 100…179 5.2…8.3    69…148
1improved from the value 0.7 % by using the proposed model fitting 
 
 
An error of 1 % in total dose results in average ∆TCP of 2.7 % and ∆NTCP of γNTCP %, where 
γNTCP is normalized slope of a NTCP curve. The maximal effect of the proposed actions in 
Table 6 is about 8 % facilitating the avoidance of significant decrease of 21 % in TCP or 
increase of 8γNTCP  % in NTCP. The maximal effect is significant also for the NTCP of the 
major salivary glands being 8 %*1.2 %/% ≈ 10 %. 
 
Improvement of the SD 
 
In this chapter, the uncertainty of total dose (1SD) achievable by using the methods, 
suggestions and criteria proposed in this thesis are underlined and the SDs achievable 
otherwise are expressed in italics. The uncertainties are combined like independent Gaussians. 
The estimated uncertainty of dose related to the choice of a QC program for output is between 
0.4 and 2.0 % (1SD). The uncertainty of dose measurements estimated by the IAEA is 1.2 % 
(1SD) when components interpreted to be related to measurement reproducibility are removed 
(factors 1-3 in chapter 2.2.1.). The uncertainty of central axis beam data was determined to be 
between 0.6 and 0.9 % (1SD). The combination of these factors results in “baseline” 
uncertainty of dose being between 1.4 and 2.5 % (1SD). The uncertainty of dose calculation 
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and physical treatment planning of 3-4 %, estimated by several groups, is interpreted here as 
2SD with the SD being about 2 %. By combining this to the results obtained above, the 
uncertainty of dose is between 2.4 and 3.2 % (1SD). 
 
Acceptable uncertainty of dose remaining for other factors (such as positional errors) to reach 
the strictest recommended overall accuracy requirement for dose of 3 % (1SD) is between 1.7 
and 0 % (1SD). To reach the more relaxed recommended overall accuracy level of 5 % (1SD), 
the remaining acceptable uncertainty is between 4.4 and 3.8 % (1SD). The achievement of 
these overall accuracy levels for dose results in that the SD of TCP and NTCP is on the 
average about 8.1…14 % and 3γNTCP …5γNTCP, respectively, where γNTCP is normalized dose 
response slope for a complication. 
 
Salivary glands 
 
For the major salivary glands, the SD of ∆Ds estimated above has quite small effect on the SD 
of the ∆NTCPs being about 3.2 %*1.2 %/% ≈ 3.8 %. As was presented in chapter 5.5.1., 
patient position correction in head and neck IMRT based on bony landmarks results in a SD 
of 7.6 % for the glandular Dmeans. By roughly assuming from literature data (Robar et al. 
2007, Vakilha et al. 2007, Lee et al. 2008a, Lee et al. 2008b) that the deformation and 
movement of parotid glands toward patient midline has a variating component of about 6 % 
(1SD), the combined effect of positional shifts remained on the Dmeans of the parotid glands is 
≈ 10 % (1SD) in the current data. This results in the SD of NTCPs of about 10 %*1.2 %/% ≈ 
12 %. Geometric accuracy clearly remains the most crucial factor for the sparing of the major 
salivary glands as far as physical criteria are concerned. The dose gradient within the glands 
can be converted into the gradient of the ∆NTCP resulting in the value of 3.3 and 3.7 %/mm 
for the parotid and submandibular glands, respectively. 
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6. DISCUSSION 
 
 
6.1. ANALYSIS OF QUALITY CONTROL DATA 
 
Time trends 
 
Systematic drifts were observed in accelerator output and calibration of CC device. Empirical 
models were found suitable for quantification of normal (no malfunctions) drifts for the 
investigated equipment. 
 
Interestingly, the output of the Clinac 2100 CDs tended to increase with time while that for 
the 600 CDs tended to decrease with time. Similarly, increasing output trend has been 
reported for the 2100 CD (Luketina and Greig 2004) and the 2300 CD (Ravichandran et al. 
2007), and decreasing trend for the 600 CD (Ravichandran et al. 2007). Since possible shifts 
in beam energy and profiles were checked and corrected before each output measurement, the 
obtained output drifts were attributed to the dose monitoring capability of accelerator. 
Changes in this capability may be due to chemical gas emission from chamber electric 
insulators, minor or major leakage of a sealed chamber and drifts in measurement electronics 
(Greene 1986). The decreasing output trends observed for the 600 CDs suggest increasing 
sensitivity for dose monitoring while the increasing output trends observed for the 2100 CDs 
suggest a decreasing sensitivity for dose monitoring (both accelerators have sealed monitoring 
chambers with metal plates). The investigation of the contribution of the above factors to the 
observed time trends was beyond the scope of this study. 
 
The average time of 18 ± 12 months observed for an output drift of 2 % is remarkably longer 
than the most recommended output measurement time intervals, ranging from 1 week to 1 
month. Because of the large variety of output trends, including also steep trends related to 
some accelerators just after commissioning, it is obvious that the obtained distributions 
represent quite realistic samples of normally observable long-term output variations for the 
investigated accelerator types. The long average drift time together with great variance in drift 
times indicate that the use of individual output measurement time intervals would be a more 
time saving procedure than the use of a common measurement time interval (Puurunen et al. 
1985). By using the presented output modelling, current trends in outputs can be quantified 
and thus accelerator-specific time intervals for the output measurements can be approached. 
The results suggested that it is reasoned to apply a short output measurement time interval for 
a new Varian accelerator just after the commissioning. 
 
The use of the presented long-term output modelling has some practical limitations. The rate 
of output adjustments may have an effect on the output stabilization. Despite drifts in beam 
energy and profile are maintained within narrow limits, they may have a slight effect on the 
determined output trends. Reproducibility of the measurements sets a limit for the number of 
data points needed for accurate determination of a time trend. Due to all these uncertainties, 
the values of the model parameters should be interpreted cautiously and be recalculated after 
each output measurement to estimate current output trend. 
 
Dosimetrically significant malfunctions, repairs, adjustments and also wide output 
adjustments may cause unexpected shifts or complex fluctuations on the output level and may 
limit the use of the output modelling. In connection with this kind of a repair or an 
adjustment, the collection of new set of data for the model fitting may be required. The ageing 
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of an accelerator, without any malfunctions, may increase the risk of unexpected output 
behaviour (Roth et al. 1998), especially with accelerators having unsealed monitor chambers 
with aluminium plates (Blad et al. 1996). Despite all these limitations and disadvantages, 
however, the proposed output modelling was feasible for 7 of 8 accelerators during the whole 
observation period. Thus it seems to serve as a useful tool in QC and also in the optimization 
of QC program. For curiosity it should be mentioned that modelling of time trends for QC 
purposes has also been suggested for other technical parameters such as gun current 
considered to facilitate the evaluation component “health” and the detection of abnormal 
behaviour related to malfunctions (Crichton et al. 1999, Haas et al. 2000). 
 
Periodic output changes from ± 2 % to ± 3 % have been reported by using unsealed CC 
instruments for output not correcting for temperature and pressure (Saw et al. 1997, Watanabe 
2000). This should be taken into account in the estimation of short-term output trends from 
the CC measurements and the stability of the calibration of a CC device. The adjustment of 
dose rate, RF power or RF frequency may cause a shift in the calibration factor of a CC 
device. This should be corrected or collection of a new data set may be required for the 
estimation of device stability. 
 
Reproducibility of measurements 
 
The fitting errors of the long-term output models included random errors of the output 
measurements, incompleteness of the output models and random short-term shifts in outputs. 
Since the fitting errors were comparable with the differences of the comparative 
measurements between the hospital and STUK, the fitting errors seemed to reflect the 
reproducibility of the local output measurements. The comparative measurements were 
independent but they were, however, carried out in the same environmental conditions 
(humidity) and by using the same QI value resulting in potential underestimation of the local 
measurement reproducibility. By accounting the uncertainty due to the former estimated by 
the IAEA (0.4 %) (IAEA 2000) and the effect of the currently estimated uncertainty of the QI 
(0.5 %) on the calibration factor of a reference chamber being ≤ 0.1 % (1SD), the estimated 
uncertainty of the local output measurements becomes about 0.6 % (1SD). 
 
The estimated reproducibility of the local output measurements was 0.5 % (1SD) and is 
remarkably better than the uncertainty of 1.4 % (1SD) estimated by the IAEA (2000). The 
estimation done by the IAEA is for a group of beams and ionization chambers including 
errors that are both systematic and random for an individual beam and chamber. The 
estimation and correction of such systematic errors, e.g. an error due to the use of the beam QI 
for the determination of the calibration coefficient for a reference ionization chamber, can not 
usually be approached by a user. Therefore, the measurement reproducibility level that can be 
estimated by a user is due to random errors. Similar reproducibility values of 0.4 % (1SD) for 
the output measurements and 0.8 % (1SD) for the CCs have been reported (Luketina and 
Greig 2004). 
 
In principle, the high reproducibility of output measurements enables the lowering of the 
action level from the currently recommended value of ± 2 %. It was observed that 2.4 % of 
the output measurements were clearly outlying from the trends of other measurements and 
from the CCs. It would thus be anticipated that the lowering of the action level under ± 1.5 % 
(≈ 3SD) might lead to small fraction of unnecessary output adjustments. To approach even 
lower action levels, the indentification of outlying or erroneous output measurements should 
be improved. This can be approached by using the proposed model fitting for the output 
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measurements, the CCs and the stability of a CC device and by careful comparison and 
interpretation of these results.  
 
 
6.2. ESTIMATION OF EFFICACY OF QUALITY CONTROL PROGRAMS 
 
 
The developed method offers a tool to estimate the efficacy of QC programs for output levels 
on a statistical basis. The results obtained for single linear output changes are suitable for 
individual accelerators, while the results obtained for the distributions of output changes 
provide long-term estimations for a set of accelerators. However, if the average value of the 
output changes for a given set of accelerators differs remarkably from zero, the results 
obtained for a single output change corresponding to the average value may provide a more 
realistic estimation. 
 
The fraction of unacceptable treatments (with |∆D| > 2 %) could be maintained when the 
output measurement time interval is doubled, if the action levels of the QC measurements are 
lowered. In principle, this enables the optimization of the measurement interval while 
maintaining the treatment quality. Lowering of the action levels requires high measurement 
reproducibility to avoid unnecessary or even erroneous output adjustments. The recognition of 
erroneous measurements can be improved by using the proposed model fitting of the results 
of the QC measurements. The most important limitation to the use of a prolonged output 
measurement time interval is the quality of the CCs related to both the equipment technology 
and the calibration procedure. A method to improve the calibration procedure was proposed in 
the section 5.1.3. Naturally, CCs should also be carried out for beam energy and symmetry 
parameters having an effect on the results of the CCs of output. When time interval for output 
measurements is aimed to be prolonged, it is useful to verify the stability of a CC device with 
shorter intervals e.g. through output measurements carried out in a solid phantom for only one 
nominal beam energy. 
 
The presented estimations of output spreads were obtained by assuming that the long-term 
average of the drifts in the CC calibration is zero. The estimations are valid only when these 
drifts are recoverable or when systematic calibration drifts are known and their effect is 
corrected. This assumption was made to maximize the generality of the results since long-
term drifts may depend drastically on a device used. The validity of the CC reproducibility 
level used in the estimations can be verified for a device by using the proposed model fitting. 
 
The spread of total doses achievable by using a QC program was presented cautiously by 
using the 99 % limits of the ∆Ds obtained for the steepest empirical output shifts of up to 1.2 
%/month. The overestimation of dose spread achievable by using the longest measurement 
interval of 3 months (due to more frequent control of such unstable accelerators regardless of 
the choice of QC program) is only about 0.5 % when estimated by using the commonly 
detected output trend of 0.3%/month. 
 
The empirical distributions used for the simulation of the random errors for both the output 
and CC measurements are practically identical with the Gaussian distribution between −2SD 
and +2SD. Therefore, it is expected that the estimated 95% limits of the ∆Ds and also the 
probabilities of unacceptable treatments are generally applicable. The empirical distributions 
do not include very large errors (> 3.6SD) since they are usually identified in practice and the 
tails of the distributions are short. Therefore, these distributions provide slightly greater 
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probabilities for large errors close to 3SD when compared to the Gaussian distribution. Due to 
the principal uncertainty related to the estimation of probabilities for large measurement 
errors, the presented 99% limits of the ∆Ds should be interpreted cautiously. 
 
In practice, output is not necessarily adjusted exactly to a measured reference value as 
assumed in the presented estimations suggesting that the obtained dose spreads may be 
slightly underestimated. On the other hand, it was assumed that the results of the output 
measurements are accepted uniformly within the predefined action limits. Output may often 
be adjusted even though these limits are not exceeded and the presented dose spreads may 
slightly overestimate the dose spread achieved in this case. 
 
The SD, 95 % and 99 % limits of actual ∆Ds were estimated for 6 MV beams from the results 
of the absorbed dose measurements resulting in the values of 1.1, 1.9 and 3.2 %, respectively. 
These values are quite close to the corresponding values of 1.3, 2.2 and 3.0 %, respectively, 
estimated by using the developed method for the QC practice used in HUCH during the 
observation period (output measurement time interval up to 6 months, average action levels: ± 
1.7 % and ± 2.3 % for the output and CC measurements, respectively, ‘normal’ output 
adjustments). Great consistency in these results suggests the feasibility of the developed 
method. Slightly smaller actual values may be due to the use of anticipatory output 
adjustments for some steep systematic output trends. 
 
 
6.3. DOSE CALCULATION ACCURACY 
 
Photon calculation accuracy in Finland compared with the international level 
 
The current analysis revealed that the OF and PDD data in the Finnish RT centres deviated 
more than ± 2 % from the current averaged data for about 6 and 10 % of the investigated 
beams, respectively. Quite similar percentages of about 4 and 13 %, respectively, have been 
reported by the RPC in the USA (Bencomo et al. 1999), obtained by comparing mailed copies 
of measured beam data for 235 photon beams (from 75 centres) with the reference data 
constructed by the RPC. In the UK, an on-site dosimetric review for 159 photon beams 
(through ionization chamber measurements at a 5 cm depth) revealed that the mean ± SD of 
differences between measured and calculated central axis dose were 0.3 ± 1.5 % (range from -
4.0 to 6.6 %) for FSs of 5x5, 10x10 and 15x15 cm2 (Thwaites et al. 1992). The corresponding 
differences in the current study were 0.0 ± 1.2 % (range from -2.5 to +3.9 %), respectively 
(obtained for the same FSs by omitting the correction of the measured differences for output 
shifts since this was not done in the referred study). Dose calculation errors exceeded the limit 
of ± 3 % in about 6 % of the investigated beams in Finland. The percentage is significantly 
lower than 23 % obtained for such large deviations in OFs alone observed in the ESTRO 
EQUAL-program (Ferreira et al. 2000) (obtained for 227 open 7x7, 20x20 and 7x20 cm2 
fields at a 10 cm depth). The comparison of the current results with those obtained in the 
EQUAL, however, is limited mainly due to different measurement techniques and 
contributions of set-up errors (averaged ion chamber measurements in this study versus single 
TLDs in the EQUAL). 
 
Achievable calculation accuracy level for central axis dose with the PBC algorithm 
 
The current results suggest that the uncertainty of central axis dose calculation due to 
uncertainty of measured beam data is about 0.9 % (1 SD) with range from -3.3 to 3.2 % for 
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the investigated beams. By considering together the SD of the averaged OFs (0.5 %), the 
reproducibility of the local PDD measurements (0.3 %) and the percentage of test fields 
having calculation accuracy within ± 1 % (79 %), it can be concluded that the calculation 
accuracy level within ± 1 % is achievable for open square fields in water with reasonable 
effort and should, therefore, be recommended. As a matter of fact, the SD of the OFs includes 
inter-accelerator differences and gives, therefore, too pessimistic estimation for 
reproducibility of OFs measured for a single accelerator. An accuracy level of ± 1.5 % is 
achievable for elongated rectangular fields (accounting for the observed systematic 
underestimation). These conclusions are consistent with the recommendations made by the 
AAPM (Fraass et al. 1998). The large observed calculation errors suggest that the quality of 
basic beam data should always be verified to obtain relevant inter-centre comparisons of dose 
calculations, such as comparison of different TPSs (Kosunen et al. 1993, Venselaar and 
Welleweerd 2001). 
 
The use of reference beam data 
 
The current results indicated that when dose calculation accuracy was within ± 1%, the 
consistency of beam data was within about ± 1 % (at least up to a 10 cm depth) for all the 
investigated accelerators. Greater SD with FSs ≥ 30x30 cm2 may be due to limited size of 
water phantom used for the beam data measurements. The use of the current averaged data 
sets proved useful in the detection of reasons for large dose calculation errors exceeding ± 
2%. These together suggest that reference data sets can be used for accurate QC of beam data. 
The data sets obtained for the 6, 15 and 18 MV beams of Clinac 2100 CDs have high 
confidence due to several individual beams investigated in these nominal energy groups. The 
generality of the data obtained for the other investigated beams may be limited due to fewer 
individual beams analyzed. These data sets, however, were also published because they 
provided accurate dose calculations for the investigated beams. By investigating beam data 
from 2350 photon beams, the RPC (Followill et al. 2004) demonstrated that dosimetric beam 
data are in an agreement within ± 2 % for individual accelerators of same manufacturer, 
model and energy. Since the data were not corrected for measured calculation accuracy, it is 
not known to what extent the observed variation is caused by measurement errors and real 
variations in beam characteristics. The accuracy of the reference data, however, may be 
limited due to slight differences in the geometry of treatment head, flattening filter and 
monitor chamber. Therefore, accurate beam data measurements should not be replaced with 
the use of reference data. 
 
Some current accelerator models, such as tomotherapy units, are supplied with their own TPS 
ready configurated and the user only verifies the accuracy of the dose calculation algorithm 
through point measurements. This rises a question how to confirm that the algorithm is tuned 
to result in best possible calculation accuracy for maximal number of clinical situations. 
 
The current results support the previous findings of high consistency in beam data for the 
Clinac 600 CDs and 2100 CDs. The averaged OFs (at dmax) obtained for the 6 MV beams of 
the 2100 CDs are consistent within 0.4 % with those reported by Cho et al. (2005) and by 
Watts (1999). For the 15 MV beams of the 2100 CDs, the current averaged OF data were 
consistent within 0.4 % with those reported by Watts (1999). For the 18 MV beams of the 
2100 CDs, the current OF data were consistent within 1.0 % with the values presented by 
Followill et al. (2004). For the 6, 15 and 18 MV beams of the 2100 CDs, the averaged PDDs 
at a 10 cm depth were within 0.7 % with those reported by Coffey et al. (1980), within 0.7 % 
with those reported by the BIR (1996) and within 1.0 % with those reported by the BIR 
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(1996), respectively. The averaged PDDs at a 10 cm depth obtained for the 4 MV beam of the 
Clinac 600 CD and for the 6 (old filter) and 10 MV beams of the Clinac 2100 CDs were 
within 0.5 % with the values published by the BIR (1996). The data published by Fontenla et 
al. (1992) were the best match found within 0.8 % for the averaged PDDs at a 10 cm depth for 
the 6 MV beams of the 600 CDs. A more detailed analysis concerning the use of reference 
data for different accelerator models has been performed by the RPC (Followill et al. 2004). 
 
The current value of the parameter A ≈ 1.5 in the equivalent square field relation (Eq. 15) 
obtained for the Clinac 2100 CDs is consistent with the value A = 1.5 reported for head-
scatter photons of the 2100 C (Kim et al. 1997) and the 2100 CD (Zhu et al. 2001). On the 
contrary, the current value of A ≈ 1.3 obtained for the 600 CDs is slightly smaller than the 
value A = 1.5 reported for head-scatter photons from the 6 MV beam of the Varian 6/100 (Zhu 
et al. 2001). Smaller collimator exchange effect observed for the 600 CDs when compared to 
that of the 2100 CDs is due to thicker shielding around a monitoring chamber partly 
eliminating radiation backscatter from the upper collimator jaws to the monitoring chamber 
(Yu et al. 1996). The current results suggest that the exchange effect of the collimator jaws on 
the OFs is smaller at a 10 cm depth than at dmax being understood by a lower amount of low 
energy extrafocal radiation from treatment head at 10 cm when compared to that at dmax (Liu 
et al. 1997). The effect of extrafocal radiation is more prominent in the 5x30 cm2 field than in 
the 30x5 cm2 field explaining the systematic underestimation of dose calculations observed in 
the 5x30 cm2 field at a depth of 10 cm when the PBC dose calculation algorithm is used. 
 
 
6.4. EFFECT OF SET-UP ERRORS 
 
 
In this thesis, positional shifts of the bony structures near the major salivary glands were 
determined to approximate positional shifts of the glands by using the conventional method of 
patient set-up verification in head and neck IMRT. The method is based on two orthogonal 
portal images taken from one to three times a week and by correcting for set-up errors 
exceeding the predefined 1D tolerance. Better positional accuracy is expected with current 
cone beam CT implementations such as Varian On-Board Imager (OBI). However, the 
current results of the observed positional errors of the bony structures in different orthogonal 
directions (means and SDs) were consistent within 1 mm with those obtained by using OBI 
(Mechalakos et al. 2007). The current SDs obtained for the systematic positional shifts are 
close to the average of the values reported in other current studies (Hong et al. 2005, 
Guckenberger et al. 2006, Linthout et al. 2006) and are clearly smaller than the median of 
values reviewed in 2001 (Hurkmans et al. 2001). 
 
It is expectable that positional shifts of the bony structures near the major salivary glands 
result in positional shifts of the glands due to the basic anatomy but a crucial question is the 
magnitude of movement of the glands with respect to these bony structures resulting in 
positional uncertainty of the glands. According to the recent studies of several groups the 
parotid glands tend to shrink and move toward patient midline during the radiotherapy of head 
and neck cancer resulting in an increase in their Dmean (Robar et al. 2007, Han et al. 2008, Lee 
et al. 2008a). By roughly assuming constant parotid volume and shape, and by using the most 
consistent literature value for the shift toward midline of about 3 mm (Lee et al. 2007, Robar 
et al. 2007, Lee et al. 2008b), a net effect of the shift is 1.2 ± 0.5 Gy for the current data. The 
estimated magnitude is consistent with an accuracy level of 1.0 Gy reported achievable for 
Dmean by using bony landmarks (O`Daniel et al. 2007). The relative effect is about 5 % (range 
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from 0.5 to 12 %) being consistent with the results of several other studies (Robar et al. 2007, 
Vakilha et al. 2007, Lee et al. 2008a). Existence of potentially similar effect of volume 
change and movement toward patient midline has not yet been reported for the submandibular 
glands and remains unknown. 
 
The dosimetric and geometric accuracy requirements proposed for the major salivary glands 
concern overall accuracy and they are valid whether positional changes have not significant 
effect on the steepness of the dose response. The accuracy criteria were given cautiously to 
account for steep dose response and dose gradients within the glands. Steep dose response 
slopes from 4 to 5%/Gy consistent with our current results have been reported (Eisbruch et al. 
1999, Münter et al. 2004, Dijkema et al. 2008) supporting the current proposal of strict 
accuracy criteria. The effect of gland deformation may limit the accuracy level of the rEF 
achievable by using the proposed geometric accuracy criterion but the desired accuracy level 
can be approached by applying the criterion for the shift of the mass center of a gland. 
 
The slope of the linear model fitted to the steepest dose regions was expectedly too shallow 
when compared to that obtained by using the sigmoidal model. This is because of relatively 
large dose region used for the fitting of the linear model in order to reach enough data points. 
Despite this limitation, however, the use of the linear model independently confirmed the 
dependence of the rEF on the Dmean providing an estimate of the minimal steepness of the 
dose response curve. 
 
In the current work, biological effects observable only 6 months after radiotherapy was used 
as an endpoint. This was chosen cautiously since the recovery of the salivary function with 
time is individual and depends on glandular dose (Eisbruch et al. 1999, Murdoch-Kinch et al. 
2008). Conveniently, the slopes obtained for later effects do not seem to be different (Dijkema 
et al. 2008, Tenhunen et al. 2008) from those obtained for 6 months by using the same 
methodology but D50 value is greater for later effects (Dijkema et al. 2008). The current D50 
value is consistent within 2 Gy with those obtained by other groups (Eisbruch et al. 1999, 
Dijkema et al. 2008) by using Lyman dose response model and binary endpoint (complication 
or not) with complication defined as reduction of salivary gland flow below 25 %. Since some 
authors have observed (Murdoch-Kinch et al. 2008) that radiation sensitivity of 
submandibular glands may be lower than that of parotid glands, the sigmoidal model was also 
fitted separately for these glands. The obtained D50 and Γ values were within 0.3 Gy and 0.4, 
respectively, for both parotid and submandibular glands showing no significant differences. 
The observation is consistent with that of other group (Münter et al. 2004) and with that of 
our previous study carried out by using the same endpoint based on scintigraphy (Tenhunen et 
al. 2008). 
 
Salivary gland scintigraphy is estimated to detect changes of 5-10 % in parenchymal function 
due to its small observer dependency and high reproducibility (Bohuslavizki et al. 1997). The 
SD of the fitting errors of the sigmoidal dose response model was about 0.3 (= 30 %) 
containing variation in radiation sensitivity, limitations of the scintigraphic method and 
changes in gland function due to non-systematic dose deviations from the planned dose. Since 
the estimated effect of dose shifts is about 12 %, the effect of the other sources is about 27 %. 
This suggests that individual radiobiological sensitivity of a gland and its scintigraphic 
assessment remain the most prominent factors of uncertainty in the determination of the dose 
response parameters when a logistic dose response model is applied together with the Dmean. 
The use of a more sophisticated NTCP model accounting for inhomogeneous dose 
distributions within the glands might reduce the scatter of data points. The SD of the EF(0) 
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and EF(6) was about 0.2 for the patients being consistent to the estimated uncertainty of a 
similar scintigraphic method observed for the parotid glands by an other group (Firat et al. 
2006). Interestingly, by combining these uncertainties, the overall uncertainty becomes about 
0.3 (1SD) corresponding to the large variation seen in the values of the rEF. 
 
As a curiosity, the sigmoidal and linear dose response models were also fitted to the shifted 
Dmean values (shift due to the effect of uncorrected realized systematic positional error). 
Interestingly, the fitting errors of the models reduced about 10 % and the steepness of the 
fitted dose response curves increased about 10 %. Despite that actual positional shifts of the 
major salivary glands were detected potentially only partly by using the bony landmarks near 
the glands, the correction of Dmean values for the obtained positional shifts had a slight effect 
on the obtained dose response parameters. The observation is consistent to some expectations 
that any source of error may reduce the steepness of the slope of a fitted dose response model. 
The results suggest that corrections for errors made individually for the glands seem to reduce 
the scatter of the data and increase the steepness of a fitted dose response model. The 
correction of Dmean by taking into account also the deformation of a gland and its movement 
toward patient midline would be of a great interest. 
 
Several methods have been proposed to estimate the effect of random positional errors on 
dose (Ploquin et al. 2006). As suggested by the results by other groups (Samuelsson et al. 
2003, Siebers et al. 2005), an average effect of random set-up errors is much smaller than that 
of systematic errors. Since intrafractional positional shifts have also been found to be far less 
than interfractional shifts (Mechalakos et al. 2007), it can be considered that the systematic 
shifts obtained from the portal images sufficiently describe the prominent effect of positional 
shifts detectable by the portal imaging. 
 
The effect of positional shifts on Dmean values of the salivary glands depends on margins 
around the glands (PRV) and target volume used in the treatment planning (Manning et al. 
2001, Ballivy et al. 2006). This essentially determines the steepness of the dose gradients 
faced by the parts of the glands nearest to the target volume. In the current study, a margin of 
about 3 mm was used. Maximal 3D dose gradient in the current study was 2.3 Gy/mm but 1D 
gradients being about two times steeper have been reported (Prabhakar et al. 2007). 
 
 
6.5. LIMITATIONS OF BIOLOGICAL ESTIMATIONS 
 
 
The aim of the accuracy criteria is that absorbed dose is kept within acceptable limits around 
the clinical reference value which should be traceable to an absolute dosimetry standard. This 
is essential for sufficient and consistent treatment quality, multicentre trials and dose 
escalation studies. In addition to physical accuracy criteria, the extent of biological effects 
related to QC procedures should be considered. E.g. proper comparison of different treatment 
protocols requires sufficient limits for the variations of TCP and NTCP. The biological 
estimations, however, are limited due to large variation in steepness of dose response 
depending drastically on cancer type, irradiated normal tissues, biological endpoint chosen 
(Levegrün et al. 2001, Cheung et al. 2005a, b), follow-up time, treatment practice (including 
other treatment modalities), dose distributions within tissues (Levegrün et al. 2001) and 
possibly even slightly different dosimetry standards for the absorbed dose. Moreover, 
physiological factors such as differences in tumor size (Suit 1966), acute and chronic hypoxia 
(Elkind et al. 1965, Kallman 1972, Dasu et al. 2005) affect tumour dose response. As a 
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consequence, considerably steeper dose response slopes have been reported e.g. for some 
prostate cancer subgroups than for unclassified prostate cancer patients (Levegrün et al. 2001, 
Cheung et al. 2005a) complicating and limitating quantitative biological estimations even 
further. 
 
The recently reported slopes for biochemical control of prostate cancers, being from 1.4 to 
2.2, are within 95% CI consistent with the average slope of 2.7 used in the current biological 
estimations. This supports the feasibility of the presented estimations of the ∆TCPs for the 
prostate cancer (Fowler et al. 2001, Cheung et al. 2003, Cheung et al. 2005a). The existence 
of much steeper dose-response slopes should not, however, be omitted since any errors and 
variations in treatment techniques and in radiobiological tumor characteristics tend to 
decrease the slopes of the fitted TCP models (Fischer and Moulder 1975, Zagars et al. 1987, 
Thames et al. 1992). This suggests that special criteria for dose accuracy may have to be 
considered when relevant and possible. 
 
 
6.6. ARE CURRENT LEVEL AND REQUIREMENTS OF QUALITY CONTROL 
SUFFICIENT? 
 
 
The overall accuracy requirement of absorbed dose is 3-5 % (1SD) which could be interpreted 
so that the 95 % CI of the dose should be about 6-10 % (estimated as 2SD). Unfortunately, the 
uncertainty of dose related to several factors, e.g. positional errors and dose calculation, 
depends on treatment, planning and immobilization techniques rendering its accurate 
estimation limited. Therefore, the proposals for sufficient QC procedures and requirements for 
the investigated topics are given so that their contributions to the overall uncertainty are small 
when compared with those of other factors that have been reported currently achievable. In 
this light, the use of procedures stricter than the proposed ones would increase workload 
without significant improvements in overall dose accuracy. The systematic errors are summed 
linearly and random errors in squares. 
 
QC program of output 
 
The choice of an output measurement time interval has the most significant effect on accuracy 
when the interval is between 0.25 and about 2 months, while it becomes less important when 
the interval is longer than 2 months. The overall uncertainty of 1.5 % (1SD) estimated for the 
absorbed dose measurements by the IAEA (2000) does not contain the uncertainty related to a 
QC program of output. One criterion for a choice of an appropriate QC program might be that 
the uncertainty related to a QC program has not significant contribution when it is combined 
to the uncertainty of the dose measurements. By interpreting that some factors in the IAEA 
estimation are related to random measurement errors (such as long-term stability of user 
dosimeter 0.3 %, establishment of reference conditions 0.4 % and dosimeter reading relative 
to beam monitor 0.6 %), the combined uncertainty is rounded to 1.5 % (with 0.5 % precision) 
when the SD of dose spread (∆Ds) due to a QC program is up to 1.2 %. This criterion would 
require the use of a very short output measurement time interval of 1 or 0.5 month for output 
measurement reproducibility levels of 0.7 or 1.4 %, respectively. The use of the proposed 
model fitting of the QC measurement results in order to reduce the effect of random errors 
and to lower the measurement action levels from the conventional values (as seen in Table 5) 
results in that the criterion can be met even by using a long measurement interval of up to 6 
months. As far as the presented criterion is concerned, the choise of an appropriate QC 
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program depends on the reproducibility of the QC measurements, and on the handling of 
random measurement errors and long-term drifts in the stability of a CC device. 
 
Potential development of dosimetry protocols may reduce the uncertainty of the dose 
measurements. Then, acceptable uncertainty related to the use of a QC program of output 
should be reconsidered to maintain it in a sufficiently low level with respect to potentially 
reduced overall uncertainty. The presented results can be applied for such reconsideration 
provided that reproducibility of the measurements will not be significantly improved from the 
best level used for the presented estimations with potentially improving equipment 
technology. 
 
The accuracy requirement based merely on the SD of the ∆Ds is not necessarily sufficient, 
e.g. for unstable accelerators showing significant systematic time patterns in output. The SD 
of ∆Ds may be small but the average dose level may be considerable different from zero 
and/or significant fraction of total doses may exceed unacceptable limits. Therefore, maximal 
limits achievable for the ∆Ds should also be considered in the estimation of an appropriate 
QC program. The estimation of these limits is difficult due to uncertainty related to the 
recognition of potential large output deviations and large measurement errors in practice. As a 
general rule, the results suggest the use of a short output measurement time interval when the 
measurement reproducibility level is poor. For the poorer measurement reproducibility level 
of 1.4 %, the use of a short measurement interval of 1 month results in similar 99 % limits of 
the ∆Ds as the use of a longer interval of 3 months for better measurement reproducibility of 
0.7 %. For poor measurement reproducibility level close to 1.4 %, the use of a long interval of 
3 months seems to be insufficient since maximal ∆Ds are about ± 5 % being about half of the 
acceptable limits for the overall dose accuracy. The use of a measurement interval of 1 week 
keeps the ∆Ds practically within the redefined action levels independently from the 
measurement reproducibility. The use of the proposed output modelling of the QC 
measurements results in that the use of a long output measurement interval of even up to 6 
months seems to be sufficient (as seen in Table 5) consistently to the criterion based on the 
SD of the ∆Ds. 
 
The use of the proposed model fitting of the QC measurement results enables the optimization 
of resources spent on workful output measurements while maintaining treatment quality with 
the investigated accelerator types (as was seen in Tables 5 and 6). It is interesting to notice 
that after the publication of the study II, doubling of output measurement time interval by 
simultaneously reducing measurement tolerance by about 0.2-0.8 % based on accelerator 
stability has also been proposed by other authors (Bouchard and Carrier 2007). As an 
alternative goal, the spread of output can be significantly reduced improving treatment quality 
when output measurement time interval is not changed. Anticipatory adjustment technique is 
recommended for output. In such technique, systematically increasing output level is adjusted 
to a value below the measured reference value and decreasing output to a value above the 
measured reference value. If the measurement reproducibility is close to 1.4 % or even worse, 
improvements in measurement practice or equipment should be considered. The choice of 
appropriate general output measurement time interval has been discussed so far but the use of 
individual measurement intervals seems to be the most optimal procedure. Especially new 
accelerators may have to be controlled frequently just after commissioning. Output stability 
and appropriate time intervals can be estimated and updated by using the proposed model 
fitting. The ultimate ‘truth’ for the choice of a sufficient QC program remains unknown due to 
its dependence on the uncertainty of other factors being case-specific. The results and 
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suggestions presented in this thesis, however, provide some general advice and should 
facilitate in the choice of an adequate QC program for output. 
 
Workfull output measurements carried out in a water tank can not easily be replaced by less 
workfull and equally accurate measurements. Some QC programs accept the use of PMMA or 
solid water phantom measurements from weekly to monthly basis to minimize the effect of 
potentially poor long-term stability of a device used for the daily CCs (Kutcher et al. 1994, 
IPEM 1999). Then, water tank measurements are carried out rarely, e.g. at least annually. 
Problems may arise, however, if the solid phantom measurements are used only to check 
output constancy and they are not converted into water tank measurements. Due to finite 
reproducibility of water tank measurements, output level may be shifted. Therefore, accurate 
conversion should be carried out and rare water tank measurements should be used to regular 
verification of the conversion due to potential changes in phantom material. The currently 
proposed model fitting method should be usefull also in the evaluation of the conversion. 
 
Beam data and dose calculation  
 
The importance of QC for basic beam data was demonstrated by showing a few dose 
calculation errors between 2-3 % in the open rectangular test fields exceeding international 
recommendations of calculation accuracy for such fields. These systematic errors accumulate 
with uncertainty of other sources jeopardizing the fulfilment of the accuracy recommended 
for clinical dose calculation and absorbed dose within a patient. Therefore, the best accuracy 
level practically achievable should be aimed at for the open rectangular fields to ensure 
sufficient quality of basic beam data used for TPS. 
 
As reviewed in chapter 2.3.2., several groups have estimated that the uncertainty related to the 
dose calculation and physical treatment planning is typically about 3-4 % most likely 
including small level of uncertainty (≈ ± 1 %) related to basic beam data. This is about half of 
the overall acceptable uncertainty. In this light, it seems that systematic errors in beam data 
should not exceed the value of about ± 1 % justifying the strict accuracy criteria proposed for 
central axis beam data for field sizes from 5x5 to 40x40 cm2. 
 
The choice of appropriate dose calculation algorithm should also be considered in QA 
procedures. E.g. for still commonly used pencil beam convolution algorithm large calculation 
errors exceeding 10 % have been reported in inhomogeneous media (Knöös et al. 1995). For 
static beams, the QC of central axis beam data is the most important procedure but more 
elaborate tests are required to evaluate the performance of calculation algorithms in practical 
situations. 
 
For the head and neck IMRT, the clinically commonly used PBC and superposition 
convolution algorithms tend to underestimate the mean dose of the parotid glands by about 4 
% when compared with MC techniques (Schwarz et al. 2003, Boudreau et al. 2005, Sakthi et 
al. 2006, Mihaylov et al. 2007). The underestimation seems to be rather systematic than 
random for an individual gland and, therefore, its effect is included in the dose response 
parameters obtained for the glands by using dose values calculated by using these algorithms. 
 
Positional verification in head and neck IMRT 
 
Positional errors and their effects were investigated only in a special case of salivary gland 
sparing head and neck IMRT. In that technique, patient position verification is carried out 
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conventionally based on bony landmarks near the glands detected by the portal imaging. The 
literature data reviewed in section 6.4. suggest, however, that the parotid glands tend to shrink 
and move toward patient midline during the treatment rendering the positioning based on 
bony landmarks inaccurate. In that section it was estimated (based on the current and 
literature data) that positional corrections based merely on the bony landmarks near the major 
salivary glands seem to reduce the positional errors of the glands roughly to about half of their 
actual values (O`Daniel et al. 2007). Corrective actions based on positional shifts of rigid 
anatomy may not be adequate, especially if both of the parotid and/or submandibular glands 
are intended to be spared. According to literature, the average shift toward midline may be 
about 3 mm being as large as the currently proposed geometric accuracy criterion for the 
glands. In this light, the currently proposed accuracy requirements might be approached on 
the average by using the conventional patient position verification based on portal imaging 
provided that all detected systematic positional errors could be completely corrected. Pursuing 
this, however, raises questions whether the conventional verification method based merely on 
daily images and tolerance for 1D shifts is accurate enough in the detection of very small 
systematic 3D shifts. One approach may be a strategy based on sequential estimations of 
systematic shift from the portal, kV or CT images accumulating during treatment. Patient set-
up is corrected for the obtained systematic error, not only for random error exceeding the 
tolerance of 1D shifts. 
 
Considerable variation with range from -2 to 12 mm has been reported for the shifts of 
individual parotids toward patient midline (Robar et al. 2007, Vakilha et al. 2007, Lee et al. 
2008b). This suggests that sparing of parotid function may be compromised for some patients 
even when all systematic positional shifts are corrected based on the bony landmarks. The 
detection and correction for tissue deformations and movements with respect to bony 
structures can be currently approached with the use of adaptive radiation therapy technique 
and deformable structure fitting (Han et al. 2008, Lee et al. 2008a). In such technique, the 
dose distribution can be replanned according to current patient anatomy. The technique seems 
promising and may prove useful in head and neck IMRT. Slight improvement of 5 % * 1.2 
%/% ≈ 6 % may be expected on the average in spared parotid gland function (estimated by 
using current dose response slope and literature data of the relative dose effect). Due to large 
variation in biological data, however, it is not clear whether all possible positional corrections 
and adaptive radiotherapy crucially reduce the variation of NTCP of the glands rendering the 
estimation of outcome more accurate for an individual gland and patient. The question will 
hopefully be answered in future by collecting dose response data with dose errors due to all 
positional shifts corrected. 
 
The presented accuracy requirements should be adopted when a glandular mean dose is close 
to about 23-37 Gy. Due to differences in dose gradients between individual treatment plans, 
geometric accuracy criterion of the major salivary glands should be evaluated individually for 
each treatment plan e.g. by simulating set-up errors. For this purpose, the accuracy 
requirement obtained for the Dmean can be used. 
 
The accuracy of glandular mean dose may be affected by several system related sources of 
errors when IMRT technique is being used. Systematic errors of MLC leaf movements of 1 
mm may cause about 10 % differences in Dmean values of the parotids (Mu et al. 2008) 
requiring strict quality assurance. 
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7. SUMMARY AND CONCLUSIONS  
 
 
The aspects investigated in this thesis have an impact on the accuracy of absorbed dose in 
radiation therapy. These are reproducibility of dosimetric quality control (QC) measurements, 
stability of accelerator radiation output, effectiveness of a chosen dosimetric QC program, 
accuracy of beam data used to configure dose calculation algorithm and patient positioning. 
Methods, suggestions and criteria were proposed to improve dose accuracy and to optimize 
workload related to dosimetric QC. These were demonstrated to be applicable in QC of the 
investigated Varian Clinac 600 and 2100 CDs having sealed monitoring chambers in normal 
clinical situations. 
 
The developed method revealed that appropriate choice of a dosimetric QC program should 
take into account the measurement reproducibility and output stability. A method based on 
empirical model fitting of QC measurement results was found suitable for the quantification 
of these factors. The change of measurement action levels was shown to have more prominent 
relative effect than the change of measurement time interval. The proposed model fitting 
facilitated identification and reduction of random measurement errors enabling the lowering 
of measurement action levels. As a consequence, workload of dosimetric measurements can 
be significantly reduced by prolonging output measurement interval from 1 month to even 6 
months while maintaining treatment quality. Alternatively, by maintaining the workload, dose 
accuracy can be improved by even about 3 %. The method can be easily incorporated in the 
electronic archives of QC results. 
 
The resources spend on QC measurements can be further optimized if individual 
measurement time intervals are used for the accelerators instead of a common measurement 
interval. Frequent checks were reasoned for some accelerators just after the commissioning 
but these accelerators seemed to stabilize with time. The proposed empirical model fitting was 
found suitable for the evaluation of individual measurement time intervals. 
 
The importance of QC for beam data used for the dose calculations was demonstrated by 
showing errors of up to about 3 % in such data. The magnitude of these errors was 
comparable to the benefit obtainable by using a short output measurement time interval. 
Robust reference beam data sets were constructed for the Varian Clinac 2100 CDs. They were 
shown useful in the identification of error sources and accurate tools for the QC of beam data. 
The use of strict accuracy criterion of ± 1 % was found justified for central axis beam data. 
 
Required dosimetric QC actions were presented for pursuing even the strictest overall dose 
accuracy recommendation of 3 % (1SD). Maximal combined effect of the investigated 
dosimetric QC actions was up to about 8 %. It is expected that improvement of dose accuracy 
makes the modelling and estimation of biological effects more reliable, i.e., tumor control and 
normal tissue complications. 
 
In the head and neck IMRT, narrow tolerances of ± 2.4 Gy and ± 3 mm were proposed for 
dosimetric and positional accuracy of the major salivary glands, respectively, based on the 
dose response obtained for the glands. These facilitate the evaluation of performance of 
position verification methods and the improvement of the prediction of spared salivary gland 
function. The current results combined with literature data suggest, that the proposed 
tolerances can be met on the average if all systematic positional errors detected from the bony 
landmarks near the glands can be corrected. 
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